<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Treatment of relapsed or refractory follicular lymphoma</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Treatment of relapsed or refractory follicular lymphoma</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Treatment of relapsed or refractory follicular lymphoma</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Arnold S Freedman, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jonathan W Friedberg, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Andrew Lister, MD, FRCP, FRCPath, FRCR</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Rebecca F Connor, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 21, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Follicular lymphoma (FL) is the second most common type of non-Hodgkin lymphoma (NHL). It is the most common of the clinically indolent NHLs defined as those lymphomas in which survival of the untreated patient is measured in years. (See  <a class="medical medical_review" href="/d/html/4716.html" rel="external">"Classification of hematopoietic neoplasms"</a>.)</p><p>The vast majority of patients treated for FL will have an initial response to therapy with 40 to 80 percent demonstrating a complete response, depending on the initial regimen used. However, conventional therapy for FL is not curative and most of these patients will ultimately develop progressive disease. In addition, less than 10 percent of patients treated with initial chemoimmunotherapy will not respond to treatment (ie, refractory disease).</p><p>The treatment of relapsed or refractory FL is discussed here. The treatment of previously untreated FL (including treatment after watchful waiting) is presented separately as are the epidemiology, clinical presentation, pathologic features, diagnosis, and pathobiology of FL.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/83847.html" rel="external">"Initial treatment of stage II to IV follicular lymphoma"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/4741.html" rel="external">"Initial treatment of stage I follicular lymphoma"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/4699.html" rel="external">"Clinical manifestations, pathologic features, diagnosis, and prognosis of follicular lymphoma"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/16646.html" rel="external">"Pathobiology of follicular lymphoma"</a>.)</p><p></p><p class="headingAnchor" id="H2"><span class="h1">EVALUATION OF SUSPECTED RELAPSE OR RESISTANCE</span><span class="headingEndMark"> — </span>After initial therapy, patients are followed at routine intervals to monitor for treatment-related complications and relapse. At these visits, they are evaluated with a history, physical examination, and blood work. Imaging studies are reserved for the evaluation of suspected relapse. (See  <a class="medical medical_review" href="/d/html/4741.html" rel="external">"Initial treatment of stage I follicular lymphoma", section on 'Surveillance for relapse'</a>.)</p><p class="headingAnchor" id="H447668149"><span class="h2">Rule out histologic transformation</span><span class="headingEndMark"> — </span>We have a low threshold to biopsy prior to retreatment in order to confirm relapse and evaluate for histologic transformation. Imaging with a combined positron emission tomography/computed tomography (PET/CT) scan provides a new baseline of disease activity with information about the anatomic areas of involvement and their metabolic activity. Biopsy should aim to sample a lymph node with the highest activity on PET. Bone marrow biopsy is reserved for patients with unexplained cytopenias.</p><p>An integral part of the natural history of FL is progression to a higher-grade histologic subtype, such as diffuse large B cell lymphoma. Biopsy is critical to identify those patients with histologic transformation since the treatment and prognosis differs from those with relapsed FL. Signs or symptoms that suggest histologic transformation include the rapid progression of lymphadenopathy, infiltration of uncommon extranodal sites (excluding the bone marrow), development of systemic symptoms (eg, fever, weight loss, night sweats), elevated serum lactate dehydrogenase (LDH), and/or hypercalcemia. The evaluation and management of histologic transformation is discussed separately. (See  <a class="medical medical_review" href="/d/html/4724.html" rel="external">"Histologic transformation of follicular lymphoma"</a>.)</p><p class="headingAnchor" id="H2142993131"><span class="h2">Recognize early treatment failure</span><span class="headingEndMark"> — </span>Early treatment failure is defined as patients with FL progressing within 24 months (POD24) of initial immunochemotherapy with BR (<a class="drug drug_general" data-topicid="9323" href="/d/drug information/9323.html" rel="external">bendamustine</a> plus <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a>), R-CHOP (<a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a>, <a class="drug drug_general" data-topicid="9391" href="/d/drug information/9391.html" rel="external">doxorubicin</a>, <a class="drug drug_general" data-topicid="10045" href="/d/drug information/10045.html" rel="external">vincristine</a>, and <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> plus rituximab), or R-CVP (cyclophosphamide, vincristine, and prednisone plus rituximab), or within 12 months of single-agent rituximab. We offer these patients more aggressive therapy because they do poorly with standard treatment approaches  (<a class="graphic graphic_algorithm graphicRef119214" href="/d/graphic/119214.html" rel="external">algorithm 1</a>).</p><p>FL is a heterogeneous disease with a variable clinical course. Most patients will have a clinically indolent course requiring intermittent treatment over decades and overall survival (OS) rates that mirror the general population. In contrast, approximately 20 percent of patients have an aggressive disease course with short remission durations, frequent relapses, and shortened OS. Prognostic tools such as the Follicular Lymphoma International Prognostic Index (FLIPI) are unable to accurately discern indolent from aggressive tumors at the time of diagnosis. The best predictor of tumor aggressiveness is the duration of remission following initial treatment [<a href="#rid1">1-7</a>].</p><p>The prognostic importance of remission duration was initially shown in several prospective cohort studies (eg, National LymphoCare study), which reported inferior survival among patients progressing within 24 months of immunochemotherapy and within 12 months of <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> [<a href="#rid1">1,2,8-11</a>]. The prognostic value of POD24 was validated in a pooled analysis of 13 international clinical trials that included &gt;5000 patients treated initially with chemotherapy (49 percent), chemoimmunotherapy (46 percent), or rituximab alone (5 percent) [<a href="#rid12">12</a>]. A 24-month landmark analysis was used to report subsequent OS according to disease status at 24 months after initial treatment. Patients without POD24 were more likely to have favorable prognostic markers including a good performance status, low risk FLIPI score, female sex, and normal beta-2-microglobulin. After adjustment for gender and stratified by performance status and FLIPI, POD24 was associated with worse subsequent OS (estimated five-year OS 71 versus 94 percent; HR 3.03, 95% CI 2.65-3.47). This prognostic impact was seen in all treatment groups, including those treated with chemoimmunotherapy (estimated five-year OS 74 versus 95 percent; HR 3.58, 95% CI 2.85-4.49) and single-agent rituximab (estimated five-year OS 91 versus 98 percent; HR 3.96, 95% CI 1.24-12.64). However, the OS of those with POD24 after chemoimmunotherapy was clearly worse than that of those with POD24 after single-agent rituximab (estimated five-year OS 74 versus 91 percent).</p><p>Biopsy to confirm relapse and exclude histologic transformation is especially important in patients with early treatment failure. In a retrospective analysis of data from the PRIMA study of maintenance <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a>, 37 percent of all biopsies performed within the first year demonstrated histologic transformation [<a href="#rid3">3</a>]. In another retrospective study, clinical or biopsy proven histologic transformation was seen in 76 percent of patients progressing within 24 months of initial treatment with BR [<a href="#rid13">13</a>]. Clinical histologic transformation was defined as a sudden rise in LDH to twice the upper limit of normal, rapid discordant localized nodal growth, new involvement of unusual extranodal sites, new B symptoms, or the development of hypercalcemia. (See <a class="local">'Rule out histologic transformation'</a> above.)</p><p class="headingAnchor" id="H5"><span class="h2">Indications for treatment</span><span class="headingEndMark"> — </span>Patients with asymptomatic recurrent FL do not necessarily require immediate treatment, but should be followed closely for the development of symptomatic disease  (<a class="graphic graphic_algorithm graphicRef119214" href="/d/graphic/119214.html" rel="external">algorithm 1</a>). In general, the same indications for treatment used for first-line therapy are used at the time of relapse or progressive disease. These are presented separately. (See  <a class="medical medical_review" href="/d/html/83847.html" rel="external">"Initial treatment of stage II to IV follicular lymphoma", section on 'Indications for treatment'</a>.)</p><p class="headingAnchor" id="H150569596"><span class="h2">Relapse after RT alone</span><span class="headingEndMark"> — </span>Patients with stage I FL may be initially treated with radiation therapy (RT) alone delivered with curative intent. Patients who relapse following treatment with RT alone are treated with single-agent <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> or chemoimmunotherapy regimens used for the initial treatment of stage II to IV FL. Such regimens are discussed in more detail separately. (See  <a class="medical medical_review" href="/d/html/83847.html" rel="external">"Initial treatment of stage II to IV follicular lymphoma"</a>.)</p><p class="headingAnchor" id="H4271409542"><span class="h1">LATE RELAPSE</span></p><p class="headingAnchor" id="H3048240307"><span class="h2">Goals of care and selection of therapy</span><span class="headingEndMark"> — </span>Most patients relapsing more than 24 months after initial chemoimmunotherapy or more than 12 months after single-agent <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> will have a clinically indolent course requiring intermittent treatment over decades and survival rates that mirror the general population [<a href="#rid1">1,2</a>]. While not curative, conventional modern therapy results in serial complete or partial remissions. Treatment focuses on the alleviation of symptoms, reversal of cytopenias, and improvement of quality of life  (<a class="graphic graphic_algorithm graphicRef119214" href="/d/graphic/119214.html" rel="external">algorithm 1</a>).</p><p>Patients with asymptomatic recurrent FL do not necessarily require immediate treatment but should be followed closely for the development of symptomatic disease. Watchful waiting is unlikely to impact overall survival (OS) in this setting. The main treatment options for patients with symptomatic late relapse include:</p><p class="bulletIndent1"><span class="glyph">●</span>Immunotherapy with single-agent <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a></p><p class="bulletIndent1"><span class="glyph">●</span>Chemoimmunotherapy with an anti-CD20 antibody (eg, <a class="drug drug_general" data-topicid="91388" href="/d/drug information/91388.html" rel="external">obinutuzumab</a> or <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a>) plus chemotherapy</p><p class="bulletIndent1"><span class="glyph">●</span>Novel agents (eg, <a class="drug drug_general" data-topicid="9822" href="/d/drug information/9822.html" rel="external">lenalidomide</a>, <a class="drug drug_general" data-topicid="126937" href="/d/drug information/126937.html" rel="external">tazemetostat</a>)</p><p></p><p>Since patients with FL experience serial relapses, many will be treated with several of these options at some point during their disease course. A preferred order for their use has not been established. At each relapse, a choice among these options must consider the response to prior therapies, comorbidities that may impact eligibility for current and future therapies, how current treatment decisions may affect future therapies, and patient preference. </p><p><em>EZH2</em> mutations are seen in approximately 20 percent of FL and generally predict for more favorable disease, which responds better to all treatments. Testing for <em>EZH2</em> mutations can help guide use of the EZH2 inhibitor <a class="drug drug_general" data-topicid="126937" href="/d/drug information/126937.html" rel="external">tazemetostat</a>. We offer tazemetostat to patients with <em>EZH2</em> mutation in first relapse and to patients without <em>EZH2</em> mutation in subsequent relapse.</p><p>For most patients with late relapse, we suggest treatment with an anti-CD20 monoclonal antibody, either alone or in combination with chemotherapy or <a class="drug drug_general" data-topicid="9822" href="/d/drug information/9822.html" rel="external">lenalidomide</a>. Patients with a poor performance status may prefer single-agent <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> for its relatively low toxicity profile, especially if prior treatment with single-agent rituximab resulted in prolonged remission (eg, &gt;24 months). In contrast, patients with a good performance status may prefer chemoimmunotherapy or lenalidomide plus <a class="drug drug_general" data-topicid="91388" href="/d/drug information/91388.html" rel="external">obinutuzumab</a> for their superior response rates despite greater toxicity and no proven improvement in survival rates. Novel agents (eg, <a class="drug drug_general" data-topicid="126937" href="/d/drug information/126937.html" rel="external">tazemetostat</a>) are often reserved for multiply relapsed FL; however, lenalidomide-based combinations are an attractive option even in first relapse given initial results from studies that suggest similar efficacy and a different toxicity profile when compared with chemoimmunotherapy. (See <a class="local">'Lenalidomide plus rituximab or obinutuzumab'</a> below.)</p><p>The response assessment after the treatment of relapsed FL mirrors that used after initial therapy  (<a class="graphic graphic_table graphicRef97480" href="/d/graphic/97480.html" rel="external">table 1</a>).</p><p class="headingAnchor" id="H7"><span class="h2">Immunotherapy-based treatment</span><span class="headingEndMark"> — </span>Monoclonal antibodies directed against CD20 (ie, immunotherapy) are a key component to the treatment of patients with FL; as discussed separately, their incorporation into initial therapy results in superior response rates, progression-free survival (PFS), and OS when compared with chemotherapy alone. (See  <a class="medical medical_review" href="/d/html/83847.html" rel="external">"Initial treatment of stage II to IV follicular lymphoma", section on 'Immunotherapy-based treatment'</a>.)</p><p>Anti-CD20 monoclonal antibodies are also used, either alone or in combination with chemotherapy, in the treatment of patients with relapsed or refractory FL.</p><p class="headingAnchor" id="H8"><span class="h3">Single-agent rituximab versus obinutuzumab or ofatumumab</span><span class="headingEndMark"> — </span>When an anti-CD20 monoclonal antibody is offered as a single agent, we suggest <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> rather than <a class="drug drug_general" data-topicid="91388" href="/d/drug information/91388.html" rel="external">obinutuzumab</a> or <a class="drug drug_general" data-topicid="9523" href="/d/drug information/9523.html" rel="external">ofatumumab</a>. Rituximab appears to be at least as effective and likely better tolerated when compared with obinutuzumab or ofatumumab in this setting. </p><p>Single-agent <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> is an acceptable treatment for patients with relapsed FL who have comorbid conditions that make them poor candidates for chemoimmunotherapy and for those with a low tumor burden and/or disease progressing slowly over years  (<a class="graphic graphic_algorithm graphicRef119214" href="/d/graphic/119214.html" rel="external">algorithm 1</a>). Rituximab has a low toxicity profile and good response rates and has been shown to delay disease progression in these populations. Long-term follow-up is limited, and it is not known if OS is improved.</p><p>The ideal dosing schedule of <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> is not known. We offer a finite schedule of rituximab rather than continuing rituximab until progression. The following administration schedules were used in the randomized trials and are equally acceptable approaches:</p><p class="bulletIndent1"><span class="glyph">●</span>Intravenous <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> 375 mg/m<sup>2</sup> per week for a total of four doses [<a href="#rid14">14</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Intravenous <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> 375 mg/m<sup>2</sup> per week for four weeks followed by four additional doses administered every two months [<a href="#rid15">15,16</a>].</p><p></p><p>A subcutaneous formulation (<a class="drug drug_general" data-topicid="113786" href="/d/drug information/113786.html" rel="external">rituximab-hyaluronidase</a>) that uses a fixed dose and a shorter administration time is an acceptable alternative for patients who have tolerated at least one full dose of intravenous <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> [<a href="#rid17">17</a>].</p><p><a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">Rituximab</a> was compared with <a class="drug drug_general" data-topicid="9523" href="/d/drug information/9523.html" rel="external">ofatumumab</a> in a randomized phase III trial (HOMER) of 438 patients with rituximab-sensitive indolent non-Hodgkin lymphoma (NHL, 98 percent FL) relapsed greater than six months after completing the last prior treatment with single-agent rituximab or a rituximab-containing regimen [<a href="#rid18">18</a>]. When compared with ofatumumab, rituximab was at least as effective in terms of overall response rate (ORR, 66 versus 50 percent) and PFS (median 21 versus 16 months) and resulted in a similar percentage of patients with grade 3 or greater adverse events (28 versus 37 percent). Similarly, a phase II randomized trial failed to demonstrate a PFS or OS benefit with <a class="drug drug_general" data-topicid="91388" href="/d/drug information/91388.html" rel="external">obinutuzumab</a> when compared with rituximab in 175 patients with relapsed indolent B cell lymphoma (85 percent FL) [<a href="#rid19">19</a>].</p><p>A phase II trial studied the safety and efficacy of retreatment with <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> in 57 patients with relapsed, advanced, indolent non-Hodgkin lymphoma (NHL) (92 percent FL), all of whom had previously responded to rituximab [<a href="#rid20">20</a>]. The ORR was 40 percent, with 11 percent complete remissions (CR); estimated median time to progression after treatment was 18 months. Side effects were mild to moderate (grades 1 or 2) and self-limited and resembled those seen in previously untreated patients. In another trial of 143 patients initially treated with four weekly doses of rituximab, responses to retreatment with rituximab were seen in 34 of 56 patients (61 percent) at first progression, 8 of 12 patients at second progression, and 0 of 4 patients at third progression [<a href="#rid14">14</a>]. (See <a class="local">'Antibody safety and route of administration'</a> below.)</p><p>Extending the schedule of <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> and increasing the number of doses from four to eight prolongs the duration of response but does not appear to improve OS. A study of 202 adults with newly diagnosed or relapsed/refractory FL who did not progress after four weekly doses of once weekly rituximab were randomly assigned to observation or rituximab infusions at 3, 5, 7, and 9 months [<a href="#rid15">15</a>]. After a median observation time of 35 months, patients who received extended rituximab dosing had superior median event-free survival (EFS; 23 versus 12 months). OS rates did not differ.</p><p class="headingAnchor" id="H9"><span class="h3">Chemoimmunotherapy</span><span class="headingEndMark"> — </span>Anti-CD20 monoclonal antibodies are used in combination with many different chemotherapy regimens for the treatment of relapsed or refractory FL. This approach is supported by numerous studies including a large meta-analysis that demonstrated superior response rates and OS when <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> was added to conventional chemotherapy in patients with previously treated or previously untreated FL [<a href="#rid21">21</a>].</p><p class="headingAnchor" id="H3531212567"><span class="h4">Choice of anti-CD20 antibody</span><span class="headingEndMark"> — </span>Multiple anti-CD20 monoclonal antibodies have been studied in relapsed or refractory FL. Of these, either <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> or <a class="drug drug_general" data-topicid="91388" href="/d/drug information/91388.html" rel="external">obinutuzumab</a> are reasonable agents to use in combination with chemotherapy in this setting.</p><p>For most patients with relapsed or refractory FL being treated with chemotherapy, we suggest <a class="drug drug_general" data-topicid="91388" href="/d/drug information/91388.html" rel="external">obinutuzumab</a> rather than <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a>. This preference is largely based on a randomized trial (GADOLIN) that demonstrated an OS benefit for <a class="drug drug_general" data-topicid="9323" href="/d/drug information/9323.html" rel="external">bendamustine</a> plus obinutuzumab when compared with single-agent bendamustine in the relapsed setting and extrapolation of the GALLIUM study that showed improved PFS with obinutuzumab-based regimens versus rituximab-based regimens in previously untreated advanced stage FL [<a href="#rid22">22-24</a>]. Details of the GALLIUM study are presented separately. (See  <a class="medical medical_review" href="/d/html/83847.html" rel="external">"Initial treatment of stage II to IV follicular lymphoma", section on 'Obinutuzumab-based regimens'</a>.)</p><p>In contrast, <a class="drug drug_general" data-topicid="9523" href="/d/drug information/9523.html" rel="external">ofatumumab</a> is not indicated for the treatment of FL. In a randomized trial (COMPLEMENT A+B), the addition of ofatumumab to <a class="drug drug_general" data-topicid="9323" href="/d/drug information/9323.html" rel="external">bendamustine</a> did not improve PFS or OS in rituximab-refractory indolent non-Hodgkin lymphoma [<a href="#rid25">25</a>]. </p><p class="headingAnchor" id="H564378378"><span class="h4">Choice of regimen</span><span class="headingEndMark"> — </span>The optimal chemotherapy regimen for relapsed FL is unknown and practice varies. While numerous regimens have demonstrated activity in this setting, there is a paucity of randomized trials offering direct comparisons. Accurate comparisons of response rates cannot be made across trials due to changes over time in the response assessment and response definitions. As such, a choice among chemotherapy regimens is primarily made based on the patient's exposure to prior chemotherapy, the regimens' expected toxicities, and the clinician's experience with the regimen.</p><p>At first late relapse following chemoimmunotherapy, we typically offer treatment with an anti-CD20 monoclonal antibody plus CHOP (<a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a>, <a class="drug drug_general" data-topicid="9391" href="/d/drug information/9391.html" rel="external">doxorubicin</a>, <a class="drug drug_general" data-topicid="10045" href="/d/drug information/10045.html" rel="external">vincristine</a>, and <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a>), <a class="drug drug_general" data-topicid="9323" href="/d/drug information/9323.html" rel="external">bendamustine</a>, or <a class="drug drug_general" data-topicid="9822" href="/d/drug information/9822.html" rel="external">lenalidomide</a>, depending on the patient's history of prior therapy  (<a class="graphic graphic_algorithm graphicRef119214" href="/d/graphic/119214.html" rel="external">algorithm 1</a>). As examples, a backbone of CHOP may be preferred for a patient who has previously received bendamustine, while a bendamustine backbone may be preferred for a patient who has previously received CHOP. Retreatment with bendamustine plus <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> is also reasonable for those who had a long initial remission duration (eg, five years). Initial results suggest that lenalidomide-based combinations are an attractive option even in first relapse with similar efficacy and a different toxicity profile when compared with chemoimmunotherapy. (See <a class="local">'Lenalidomide plus rituximab or obinutuzumab'</a> below.)</p><p>The data supporting the use of bendamustine-based and CHOP-based regimens are described below along with data regarding the efficacy of other regimens in the relapsed or refractory setting:</p><p class="headingAnchor" id="H2325922316"><span class="h5">Bendamustine-based</span><span class="headingEndMark"> — </span>The combination of <a class="drug drug_general" data-topicid="9323" href="/d/drug information/9323.html" rel="external">bendamustine</a> plus <a class="drug drug_general" data-topicid="91388" href="/d/drug information/91388.html" rel="external">obinutuzumab</a> (BO) or bendamustine plus <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> (BR)  (<a class="graphic graphic_table graphicRef111141" href="/d/graphic/111141.html" rel="external">table 2</a>) may be preferred for a patient who has previously received therapy that included CVP or CHOP. Some experts consider retreatment with a bendamustine-based regimen to be reasonable for those who had a long initial remission duration with BR (eg, five years). Increased deaths have been reported in patients &gt;70 years of age treated with bendamustine in the GALLIUM study [<a href="#rid26">26</a>]; when offering BR to older patients, we lower the dose of bendamustine (to 70 mg/m<sup>2</sup>) and/or limit the number of cycles. We do not routinely offer maintenance after bendamustine as it has not demonstrated a survival benefit and has associated toxicities.</p><p>Fatal and/or serious toxicities can be seen with <a class="drug drug_general" data-topicid="9323" href="/d/drug information/9323.html" rel="external">bendamustine</a>, including infusion reactions, skin reactions, extravasation injury, hepatotoxicity, infections [<a href="#rid27">27</a>], myelosuppression, and embryo-fetal toxicity. </p><p>The following trials have demonstrated high response rates with bendamustine-based therapy in the relapsed setting and a survival benefit for BO over that seen with <a class="drug drug_general" data-topicid="9323" href="/d/drug information/9323.html" rel="external">bendamustine</a> alone:</p><p>Two phase 2 trials of BR in a total of 130 patients with relapsed or refractory NHL (49 percent FL) reported response rates of 90 to 92 percent (55 to 60 percent complete) [<a href="#rid28">28,29</a>]. Median PFS was approximately two years. The most common severe (grade 3/4) toxicity was myelosuppression with leukopenia (16 to 36 percent) and thrombocytopenia (3 to 9 percent). A phase 3 noninferiority study comparing BR versus <a class="drug drug_general" data-topicid="8452" href="/d/drug information/8452.html" rel="external">fludarabine</a> plus <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> in relapsed or refractory indolent lymphoma reported higher response rates, PFS, and OS with BR [<a href="#rid30">30</a>].</p><p>In one trial (GADOLIN), 396 patients with rituximab-refractory indolent NHL (81 percent FL) were randomly assigned to six cycles of <a class="drug drug_general" data-topicid="9323" href="/d/drug information/9323.html" rel="external">bendamustine</a> alone versus six cycles of bendamustine plus <a class="drug drug_general" data-topicid="91388" href="/d/drug information/91388.html" rel="external">obinutuzumab</a> (BO), followed by obinutuzumab maintenance for two years [<a href="#rid23">23,24</a>]. The addition of obinutuzumab improved PFS (median 26 versus 14 months) and OS (HR 0.67; 95% CI 0.47-0.96). (See <a class="local">'Use of maintenance'</a> below.)</p><p><a class="drug drug_general" data-topicid="9323" href="/d/drug information/9323.html" rel="external">Bendamustine</a> was included as a chemotherapy backbone in the GALLIUM study that showed improved PFS with obinutuzumab-based regimens versus rituximab-based regimens in previously untreated advanced stage FL [<a href="#rid22">22</a>]. (See  <a class="medical medical_review" href="/d/html/83847.html" rel="external">"Initial treatment of stage II to IV follicular lymphoma", section on 'Obinutuzumab-based regimens'</a>.)</p><p class="headingAnchor" id="H961767932"><span class="h5">CHOP-based</span><span class="headingEndMark"> — </span>CHOP (<a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a>, <a class="drug drug_general" data-topicid="9391" href="/d/drug information/9391.html" rel="external">doxorubicin</a>, <a class="drug drug_general" data-topicid="10045" href="/d/drug information/10045.html" rel="external">vincristine</a>, and <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a>) plus <a class="drug drug_general" data-topicid="91388" href="/d/drug information/91388.html" rel="external">obinutuzumab</a> (O-CHOP) or <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> (R-CHOP)  (<a class="graphic graphic_table graphicRef63586" href="/d/graphic/63586.html" rel="external">table 3</a>) may be preferred for a patient with late relapse who has previously received <a class="drug drug_general" data-topicid="9323" href="/d/drug information/9323.html" rel="external">bendamustine</a>.</p><p>There is limited data evaluating the use of R-CHOP in patients who received initial treatment with rituximab-based therapy. The most common severe (grade 3/4) side effect with R-CHOP in the relapsed setting is granulocytopenia (63 percent) [<a href="#rid31">31,32</a>]. Other common side effects are generally mild to moderate alopecia, nausea, vomiting, and infusion-related reactions. There is a 1 percent treatment-related mortality rate.</p><p>Trials of O-CHOP have reported response rates as high as 96 percent in relapsed/refractory FL [<a href="#rid33">33</a>]. CHOP was included as a chemotherapy backbone in the GALLIUM study that showed improved PFS with obinutuzumab-based regimens versus rituximab-based regimens in previously untreated advanced stage FL [<a href="#rid22">22</a>]. (See  <a class="medical medical_review" href="/d/html/83847.html" rel="external">"Initial treatment of stage II to IV follicular lymphoma", section on 'Obinutuzumab-based regimens'</a>.)</p><p class="headingAnchor" id="H52897285"><span class="h4">Use of maintenance</span><span class="headingEndMark"> — </span>Some of our contributors offer maintenance therapy with an anti-CD20 monoclonal antibody (<a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> or <a class="drug drug_general" data-topicid="91388" href="/d/drug information/91388.html" rel="external">obinutuzumab</a>), while others do not. Maintenance improves PFS, but its impact on OS is not clear. Even though maintenance is designed to have a low toxicity profile, a decision regarding its use in an individual patient must take into consideration both the potential benefit from attaining a deeper response and the likelihood that this patient will tolerate the prolonged therapy.</p><p>Clinicians who choose to administer maintenance should use one of the established regimens, such as that used in the GALLIUM study (<a class="drug drug_general" data-topicid="91388" href="/d/drug information/91388.html" rel="external">obinutuzumab</a> or <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> every two months for a total of two years) [<a href="#rid22">22</a>]. Trials that have used longer courses of maintenance (eg, four years) have noted increased toxicity toward the end of maintenance [<a href="#rid34">34,35</a>]; as such, maintenance should <strong>not</strong> exceed two years. Anti-CD20 monoclonal antibodies also impose a risk of hepatitis B virus reactivation among patients positive for hepatitis B surface antigen (HBsAg) or antibodies against hepatitis B core antigen (anti-HBc). (See <a class="local">'Antibody safety and route of administration'</a> below.)</p><p>The decision to use maintenance at relapse should take into consideration whether the patient was exposed to an anti-CD20 antibody at the time of relapse. It is reasonable to offer maintenance if the relapse did <strong>not</strong> occur while the patient was receiving maintenance with that antibody. This is largely based on extrapolation of data demonstrating prolonged PFS with maintenance following initial therapy. Patients progressing while on maintenance therapy are not expected to benefit from further maintenance with that same antibody at relapse. Patients progressing on <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> maintenance are eligible for <a class="drug drug_general" data-topicid="91388" href="/d/drug information/91388.html" rel="external">obinutuzumab</a> maintenance at relapse. The use of maintenance following initial therapy is presented separately. (See  <a class="medical medical_review" href="/d/html/83847.html" rel="external">"Initial treatment of stage II to IV follicular lymphoma", section on 'Use of maintenance'</a>.)</p><p>A meta-analysis of nine trials including 2586 adult patients with FL reported that patients who received maintenance <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> demonstrated the following when compared with patients who were observed or treated with rituximab at the time of relapse [<a href="#rid36">36</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Higher rates of severe (grade 3 or 4) toxicities, especially infection-related adverse events (RR 1.67, 95% CI 1.40-2.00).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Superior rates of OS for patients with relapsed disease (HR 0.72, 95% CI 0.57-0.91), but not for those with previously untreated FL (HR 0.86, 95% CI 0.60-1.25) or if the patients were eligible for <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> retreatment at disease progression (HR 0.86, 95% CI 0.49-1.49).</p><p></p><p>Data on <a class="drug drug_general" data-topicid="91388" href="/d/drug information/91388.html" rel="external">obinutuzumab</a> maintenance in the relapsed setting are more limited. In one randomized study, <a class="drug drug_general" data-topicid="9323" href="/d/drug information/9323.html" rel="external">bendamustine</a> plus obinutuzumab followed by obinutuzumab maintenance improved PFS, but not OS, when compared with bendamustine alone [<a href="#rid23">23,24</a>]. However, because of the trial design, it is impossible to know whether the incorporation of maintenance contributed to this benefit. We do not routinely offer maintenance after bendamustine given the unclear impact on survival and concerns raised in some reports of increased fatal adverse events among patients receiving maintenance after bendamustine-based induction, especially among patients over age 70 [<a href="#rid22">22,26</a>].</p><p class="headingAnchor" id="H1184092619"><span class="h3">Antibody safety and route of administration</span><span class="headingEndMark"> — </span>The major toxicities of anti-CD20 antibodies include:</p><p class="bulletIndent1"><span class="glyph">●</span>Infusion reactions (ie, fevers, rigors, and hypotension). Less common infusion reactions include mucocutaneous reactions (Stevens-Johnson syndrome, vesiculobullous dermatitis, and toxic epidermal necrolysis). (See  <a class="medical medical_review" href="/d/html/2811.html" rel="external">"Infusion-related reactions to therapeutic monoclonal antibodies used for cancer therapy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Infections related to immunosuppression. (See  <a class="medical medical_review" href="/d/html/3939.html" rel="external">"Secondary immunodeficiency induced by biologic therapies", section on 'Monoclonal antibodies to B cells'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hepatitis B virus reactivation among patients positive for hepatitis B surface antigen (HBsAg) or antibodies against hepatitis B core antigen (anti-HBc). (See  <a class="medical medical_review" href="/d/html/3649.html" rel="external">"Hepatitis B virus reactivation associated with immunosuppressive therapy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Rarely, JC virus infection can result in potentially fatal progressive multifocal leukoencephalopathy. (See  <a class="medical medical_review" href="/d/html/1694.html" rel="external">"Progressive multifocal leukoencephalopathy (PML): Epidemiology, clinical manifestations, and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Rare cases of severe, sometimes fatal disseminated intravascular coagulation (DIC) have been reported in patients treated with <a class="drug drug_general" data-topicid="91388" href="/d/drug information/91388.html" rel="external">obinutuzumab</a> [<a href="#rid37">37</a>].</p><p></p><p>Most studies have utilized intravenous administration. A subcutaneous formulation (<a class="drug drug_general" data-topicid="113786" href="/d/drug information/113786.html" rel="external">rituximab-hyaluronidase</a>) that uses a fixed dose and a shorter administration time is an acceptable alternative for patients who have tolerated at least one full dose of intravenous <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> [<a href="#rid17">17</a>]. Randomized trials have demonstrated comparable efficacy and safety of the two formulations in patients with FL, diffuse large B cell lymphoma, and chronic lymphocytic leukemia [<a href="#rid38">38-41</a>].</p><p class="headingAnchor" id="H294194062"><span class="h2">Novel agents</span><span class="headingEndMark"> — </span>Novel agents are often reserved for multiply relapsed FL; however, novel agents are appropriate for a subset of patients in first relapse:</p><p class="bulletIndent1"><span class="glyph">●</span>We offer the EZH2 inhibitor <a class="drug drug_general" data-topicid="126937" href="/d/drug information/126937.html" rel="external">tazemetostat</a> in first relapse to the approximately 20 percent of patients with FL demonstrating an <em>EZH2</em> mutation. (See <a class="local">'Tazemetostat'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Lenalidomide-based combinations are an attractive option even in first relapse for the broader population with FL given initial results from studies that suggest similar efficacy and a different toxicity profile when compared with chemoimmunotherapy. (See <a class="local">'Lenalidomide plus rituximab or obinutuzumab'</a> below.)</p><p></p><p class="headingAnchor" id="H3018249394"><span class="h1">EARLY TREATMENT FAILURE</span><span class="headingEndMark"> — </span>Patients with FL progressing within 24 months of initial immunochemotherapy or within 12 months of single-agent <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> (ie, early treatment failure) do poorly with standard treatment approaches. Low quality evidence suggests improved outcomes with more aggressive therapy. A similar approach is used for patients with FL that is refractory to initial therapy. </p><p class="headingAnchor" id="H329262187"><span class="h2">Goals of care</span><span class="headingEndMark"> — </span>With conventional chemotherapy regimens, the approximately 20 percent of patients with early treatment failure experience frequent relapses and substantially shortened survival [<a href="#rid1">1,2</a>]. The prognostic impact of early treatment failure is discussed in more detail separately. (See <a class="local">'Recognize early treatment failure'</a> above.)</p><p>Treatment with more aggressive therapy aims to improve survival, although data supporting this approach are limited. These aggressive treatments are associated with more severe toxicity and an increased risk of early mortality. The goals of care for an individual must take into consideration his or her values and preferences with the understanding that the prognosis is poor with standard approaches.</p><p class="headingAnchor" id="H2780358243"><span class="h2">Therapeutic strategy</span><span class="headingEndMark"> — </span>There is no standard therapy for patients progressing within 24 months of initial immunochemotherapy or within 12 months of single-agent <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> (ie, early treatment failure) and practice varies widely [<a href="#rid42">42</a>]; as such, we encourage patients to participate in clinical trials whenever possible. Outside of a clinical trial, our approach depends on whether there is histologic transformation and whether the patient is a candidate for high dose chemotherapy and autologous hematopoietic cell transplantation (HCT)  (<a class="graphic graphic_algorithm graphicRef119214" href="/d/graphic/119214.html" rel="external">algorithm 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Biopsy to confirm relapse and exclude histologic transformation is especially important in patients with early treatment failure [<a href="#rid3">3,13</a>]. The treatment of histologic transformation is discussed in more detail separately. (See  <a class="medical medical_review" href="/d/html/4724.html" rel="external">"Histologic transformation of follicular lymphoma"</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patents who are eligible for HCT, we suggest chemoimmunotherapy with O-CHOP or <a class="drug drug_general" data-topicid="9323" href="/d/drug information/9323.html" rel="external">bendamustine</a> plus <a class="drug drug_general" data-topicid="91388" href="/d/drug information/91388.html" rel="external">obinutuzumab</a> with the goal of attaining a complete remission (CR). Those who attain a CR are candidates for high dose chemotherapy with autologous HCT rescue offered in an attempt to attain long-term remission. Patients with early treatment failure after single-agent <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> who achieve CR with chemoimmunotherapy may reasonably defer high dose chemotherapy until subsequent relapse. For those who are unable to achieve CR, options include serial novel agents (eg, <a class="drug drug_general" data-topicid="9822" href="/d/drug information/9822.html" rel="external">lenalidomide</a>, <a class="drug drug_general" data-topicid="126937" href="/d/drug information/126937.html" rel="external">tazemetostat</a>) with a plan for autologous HCT in CR or chimeric antigen receptor T cells (CAR-T therapy). (See <a class="local">'Chimeric antigen receptor T cells'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients who are ineligible for autologous HCT or CAR-T, or do not wish to undergo these procedures, we suggest treatment with serial novel agents rather than chemoimmunotherapy. This preference is based on short-term follow-up of trials that suggest these novel agents are effective in this setting and an understanding that responses to chemoimmunotherapy are likely to be short-lived.</p><p></p><p>Patients with early relapse are likely to require treatment with many different therapies at some point during their disease course. A preferred order for their use has not been established. At each relapse, a choice among these options must take into account the response to prior therapies, comorbidities that may impact eligibility for current and future therapies, and how current treatment decisions may affect future therapies.</p><p>As examples:</p><p class="bulletIndent1"><span class="glyph">●</span>High dose chemotherapy with autologous HCT rescue can prolong the progression-free survival (PFS) and overall survival (OS) rates of patients in CR or with minimal disease at the time of HCT. However, autologous HCT may affect bone marrow reserve. (See <a class="local">'Autologous transplant for eligible patients'</a> below and  <a class="medical medical_review" href="/d/html/4709.html" rel="external">"Autologous hematopoietic cell transplantation in follicular lymphoma"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Studies with limited follow-up suggest that CAR-T is very effective in a highly selected cohort of patients, but has substantial short-term toxicity, is technically complex, and is expensive. Otherwise fit patients with early treatment failure who demonstrate chemotherapy-sensitive disease may be ideal candidates for this approach in second or greater remission. CAR-T has largely supplanted allogeneic HCT in this setting. (See <a class="local">'Chimeric antigen receptor T cells'</a> below.)</p><p></p><p>The response assessment after the treatment of relapsed FL mirrors that used after initial therapy  (<a class="graphic graphic_table graphicRef97480" href="/d/graphic/97480.html" rel="external">table 1</a>).</p><p class="headingAnchor" id="H31594622"><span class="h2">Autologous transplant for eligible patients</span><span class="headingEndMark"> — </span>Retrospective analyses suggest that autologous HCT prolongs remissions in patients with early treatment failure  (<a class="graphic graphic_algorithm graphicRef119214" href="/d/graphic/119214.html" rel="external">algorithm 1</a>). Eligibility for HCT is primarily determined based on the patient's age, their performance status, and/or the presence of comorbid conditions. This is discussed in more detail separately. (See  <a class="medical medical_review" href="/d/html/16354.html" rel="external">"Determining eligibility for autologous hematopoietic cell transplantation"</a>.)</p><p>Several retrospective analyses have suggested that autologous HCT improves survival when compared with chemoimmunotherapy alone [<a href="#rid43">43-47</a>]. As examples:</p><p>An analysis of data from an HCT registry identified 440 patients with early treatment failure and reported the following [<a href="#rid43">43</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Autologous HCT (240 patients) – estimated five-year OS 70 percent (95% CI 64-76 percent); 5 percent nonrelapse mortality</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Matched sibling donor allogeneic HCT (105 patients) – estimated five-year OS 73 percent (95% CI 64-81 percent); 17 percent nonrelapse mortality</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Matched unrelated donor allogeneic HCT (95 patients) – estimated five-year OS 49 percent (95% CI 39-60 percent); 33 percent nonrelapse mortality</p><p></p><p>Estimated five-year survival rates were similar for autologous HCT and matched sibling donor allogeneic HCT, but worse for matched unrelated donor allogeneic HCT. On multivariate analysis, when compared with autologous HCT, matched sibling donor allogeneic HCT had a lower relative risk of mortality more than 24 months after HCT (RR 0.29; 95% CI 0.12-0.67). These five-year survival rates compare favorably to outcomes with chemoimmunotherapy alone; however, their eligibility for HCT necessitates that this group is younger and fitter, have few comorbidities, and usually have chemotherapy-responsive disease.</p><p>Another retrospective registry analysis evaluated the outcomes of 349 patients with early treatment failure [<a href="#rid44">44</a>]. When the population was analyzed as a whole, OS was similar whether or not HCT was performed. However, in a planned subset analysis, when compared with those who didn't undergo HCT, the 123 patients receiving autologous HCT within one year of treatment failure had superior OS at five years (73 versus 60 percent). A mortality benefit for early autologous HCT was maintained when the analysis was matched for age and other known prognostic variables. These results suggest that early autologous HCT may benefit those with early treatment failure. However, this analysis did not provide information on what therapies were offered at the time of relapse or how the disease responded to second-line therapy. The benefit found with HCT could be due to a more favorable response to second-line therapies.</p><p>High dose chemotherapy with autologous HCT and allogeneic HCT are discussed in more detail separately. (See  <a class="medical medical_review" href="/d/html/4709.html" rel="external">"Autologous hematopoietic cell transplantation in follicular lymphoma", section on 'Relapsed disease'</a> and  <a class="medical medical_review" href="/d/html/88808.html" rel="external">"Allogeneic hematopoietic cell transplantation in follicular lymphoma", section on 'Nonmyeloablative and reduced intensity HCT'</a>.)</p><p class="headingAnchor" id="H38490558"><span class="h1">MULTIPLY RELAPSED DISEASE</span></p><p class="headingAnchor" id="H3529273455"><span class="h2">Sequencing of therapies</span><span class="headingEndMark"> — </span>Most patients with FL experience serial relapse and will be treated with many available agents at some point during their disease course. A preferred order for their use has not been established. </p><p>Novel agents (eg, <a class="drug drug_general" data-topicid="9822" href="/d/drug information/9822.html" rel="external">lenalidomide</a>, <a class="drug drug_general" data-topicid="126937" href="/d/drug information/126937.html" rel="external">tazemetostat</a>) may be used for multiply relapsed FL. A choice is primarily made based on the patient's prior treatment, the regimens' expected toxicities, route of administration, and the clinician's experience with the regimens. As an example, lenalidomide may be preferred by some patients because of its oral route of administration, while others may prefer an intravenous regimen that incorporates treatment-free days. While testing for <em>EZH2</em> mutations can identify patients who are more likely to respond to the EZH2 inhibitor tazemetostat, responses have also been seen in patients without <em>EZH2</em> mutations.</p><p>While relapsed FL is typically sensitive to additional therapy, the depth and duration of remission generally becomes shorter with each subsequent therapy [<a href="#rid48">48,49</a>]. Treatment focuses on the alleviation of symptoms and improvement of quality of life. The response assessment after the treatment of relapsed FL mirrors that used after initial therapy  (<a class="graphic graphic_table graphicRef97480" href="/d/graphic/97480.html" rel="external">table 1</a>).</p><p>Chimeric antigen receptor T (CAR-T) cell therapy is an option for patients with multiply relapsed FL. The use of CAR-T therapy is individualized weighing disease tempo, availability of other treatments, and expected toxicity. Since most patients with relapsed FL have favorable outcomes with other, less toxic treatment options, we generally reserve CAR-T therapy for patients with multiply relapsed FL with short prior remission durations (eg, &lt;24 months). (See <a class="local">'Chimeric antigen receptor T cells'</a> below.)</p><p>Where available (eg, United States, Europe), <a class="drug drug_general" data-topicid="140391" href="/d/drug information/140391.html" rel="external">mosunetuzumab</a> is an option for patients with multiply relapsed FL and may be appropriate for use after or instead of CAR-T therapy. (See <a class="local">'Mosunetuzumab'</a> below.) </p><p class="headingAnchor" id="H2586262347"><span class="h2">Novel agents</span></p><p class="headingAnchor" id="H3341942499"><span class="h3">Lenalidomide plus rituximab or obinutuzumab</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9822" href="/d/drug information/9822.html" rel="external">Lenalidomide</a> plus <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> (R<sup>2</sup>) and lenalidomide plus <a class="drug drug_general" data-topicid="91388" href="/d/drug information/91388.html" rel="external">obinutuzumab</a> (O-R) are acceptable alternatives for the treatment of late or early relapse. While follow-up is limited, these regimens appear to have similar efficacy to chemoimmunotherapy, but different toxicity. Lenalidomide carries boxed warnings regarding embryo-fetal toxicity, hematologic toxicity, and venous and arterial thromboembolism. The rate of venous thromboembolism in patients with FL receiving lenalidomide is similar to that seen in multiple myeloma [<a href="#rid50">50</a>]. As such, we use <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> (81 mg daily) for thromboembolic prophylaxis in patients receiving lenalidomide.</p><p>Support for the use of R<sup>2</sup> comes from the following randomized trials, which have demonstrated superior progression-free survival (PFS) when compared with either agent by itself and from studies in treatment-naïve patients that show similar PFS compared with chemoimmunotherapy (see  <a class="medical medical_review" href="/d/html/83847.html" rel="external">"Initial treatment of stage II to IV follicular lymphoma", section on 'Lenalidomide plus rituximab or obinutuzumab'</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>A multicenter, placebo-controlled randomized trial (AUGMENT) evaluated the addition of <a class="drug drug_general" data-topicid="9822" href="/d/drug information/9822.html" rel="external">lenalidomide</a> to <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> in 358 patients with relapsed and/or refractory FL or marginal zone lymphoma [<a href="#rid51">51</a>]. Patients received lenalidomide or placebo for 12 cycles plus rituximab once per week for four weeks in cycle 1 and on the first day of cycles 2 through 5. The addition of lenalidomide resulted in:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Improved PFS (median 39 versus 14 months; HR 0.46, 95% CI 0.34-0.62). Data regarding overall survival (OS) are immature (estimated two-year OS 93 versus 87 percent; HR 0.61, 95% CI 0.33-1.13). </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Higher rates of infection (63 versus 49 percent) and cutaneous reactions (32 versus 12 percent). Rates of neutropenic fever were low (3 versus 1 percent). However, patients assigned to <a class="drug drug_general" data-topicid="9822" href="/d/drug information/9822.html" rel="external">lenalidomide</a> had more grade 3 or 4 neutropenia (50 versus 13 percent) and were more likely to receive growth factors (36 versus 12 percent).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a phase II trial, 91 patients with relapsed or refractory FL were randomly assigned to single-agent <a class="drug drug_general" data-topicid="9822" href="/d/drug information/9822.html" rel="external">lenalidomide</a> or to R<sup>2</sup> [<a href="#rid52">52</a>]. The addition of <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> improved the response rate (76 versus 53 percent) and median time to progression (2 versus 1.1 years) but did not improve survival. Among those receiving R<sup>2</sup>, the most common severe (grade 3/4) toxicities were neutropenia (20 percent), fatigue (13 percent), and rash (4 percent). Thrombosis occurred in 9 out of the 91 patients overall.</p><p></p><p>There are limited data regarding the use of O-R. In an open-label, phase Ib study, responses to O-R were seen in 12 of 19 patients with relapsed or refractory FL after rituximab-containing therapy [<a href="#rid53">53</a>]. Use as initial therapy is discussed separately. (See  <a class="medical medical_review" href="/d/html/83847.html" rel="external">"Initial treatment of stage II to IV follicular lymphoma", section on 'Lenalidomide plus rituximab or obinutuzumab'</a>.)</p><p class="headingAnchor" id="H1673983968"><span class="h3">Tazemetostat</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="126937" href="/d/drug information/126937.html" rel="external">Tazemetostat</a> is an oral inhibitor of enhancer of zeste homolog 2 (EZH2) that has shown activity in a small nonrandomized phase 1/2 trial that included patients with multiply relapsed FL [<a href="#rid54">54-56</a>]. Responses are seen in most patients with <em>EZH2</em> mutations and a smaller percentage of patients with <em>EZH2</em> wild-type FL. We offer tazemetostat to patients with <em>EZH2</em> mutation in first relapse and to patients without <em>EZH2</em> mutation in subsequent relapse.</p><p><a class="drug drug_general" data-topicid="126937" href="/d/drug information/126937.html" rel="external">Tazemetostat</a> is approved by the US Food and Drug Administration as a single agent for the treatment of patients with relapsed or refractory <em>EZH2</em> mutation positive FL who have received at least two prior systemic therapies [<a href="#rid54">54</a>]. To qualify for tazemetostat, FL tumor specimens should demonstrate one of the following EZH2 mutations: Y646, A682, or A692. Tazemetostat is also approved for patients with relapsed or refractory FL who have no satisfactory alternative treatment options.</p><p><a class="drug drug_general" data-topicid="126937" href="/d/drug information/126937.html" rel="external">Tazemetostat</a> 800 mg is administered orally twice a day until disease progression or unacceptable toxicity. Suggested dose modifications for toxicity are provided in the package insert in addition to dose adjustments for patients taking CYP3A inhibitors [<a href="#rid54">54</a>]. The most common toxicities are fatigue, upper respiratory tract infection, musculoskeletal pain, nausea, and abdominal pain. Tazemetostat increases the risk of secondary malignancies, including T cell lymphoblastic lymphoma, B cell acute lymphoblastic leukemia, myelodysplastic syndrome, and acute myeloid leukemia. </p><p>Efficacy and toxicity data come from a multicenter, open-label single-arm phase 1/2 trial (NCT01897571) [<a href="#rid56">56</a>]. This trial included two cohorts of patients with relapsed or refractory FL after at least two prior systemic therapies: </p><p class="bulletIndent1"><span class="glyph">●</span><em>EZH2</em> mutated FL – Among the 45 patients with <em>EZH2</em> mutated FL, ORR was 69 percent, with 13 percent CR and 56 percent PR; median duration of response was 11 months and median PFS was 14 months. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><em>EZH2</em> wild-type FL – Among the 54 patients with <em>EZH2</em> wild-type FL, ORR was 35 percent, with 4 percent CR and 31 percent PR; median duration of response was 13 months and median PFS was 11 months. </p><p></p><p>Responses were delayed with a median time to first response of 3.7 months in both groups. Toxicities were mostly grade 1 or 2 and included nausea, diarrhea, and asthenia/fatigue. Alopecia and rash were noted in 17 and 15 percent, respectively. Usually, mild hematopoietic toxicity was seen in a significant minority of patients; other laboratory abnormalities included hyperglycemia (53 percent), increased AST/ALT (20 to 25 percent), increased alkaline phosphatase (18 percent), and increased creatinine (17 percent). There were no treatment-related deaths; eight patients discontinued therapy due to an adverse event.</p><p><em>EZH2</em> mutations are seen in approximately 20 percent of FL and generally predict for more favorable disease, which responds better to all treatments [<a href="#rid57">57</a>].</p><p class="headingAnchor" id="H1673072463"><span class="h3">Other novel agents</span><span class="headingEndMark"> — </span>The efficacy and safety of other novel agents requires further study. Often, promising responses in early-phase studies are not confirmed in subsequent studies. As examples, single-arm phase 2 trials have reported low overall response rates with <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> (4 percent [<a href="#rid58">58</a>]), <a class="drug drug_general" data-topicid="91587" href="/d/drug information/91587.html" rel="external">ibrutinib</a> (21 and 38 percent [<a href="#rid59">59,60</a>]), and the combination of <a class="drug drug_general" data-topicid="107696" href="/d/drug information/107696.html" rel="external">venetoclax</a> plus <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> (35 percent [<a href="#rid61">61</a>]). As such, we do not consider these agents to be effective in this setting.</p><p>While initial studies suggest that <a class="drug drug_general" data-topicid="126183" href="/d/drug information/126183.html" rel="external">zanubrutinib</a> has efficacy in FL, we await further data prior to incorporating it into routine clinical care [<a href="#rid62">62-64</a>]. In a randomized phase 2 trial (ROSEWOOD), the addition of zanubrutinib to <a class="drug drug_general" data-topicid="91388" href="/d/drug information/91388.html" rel="external">obinutuzumab</a> improved overall response rates (69 versus 46 percent) and median PFS (28 versus 10.4 months; HR 0.50, 95% CI 0.33 to 0.75) [<a href="#rid64">64</a>]. The most common adverse effects were thrombocytopenia, neutropenia, diarrhea, and fatigue.</p><p>While previously approved by the US Food and Drug Administration (FDA), the manufacturers have voluntarily withdrawn the FL indications for the phosphoinositide 3-kinase (PI3K) inhibitors <a class="drug drug_general" data-topicid="119167" href="/d/drug information/119167.html" rel="external">duvelisib</a>, <a class="drug drug_general" data-topicid="96416" href="/d/drug information/96416.html" rel="external">idelalisib</a>, <a class="drug drug_general" data-topicid="130727" href="/d/drug information/130727.html" rel="external">umbralisib</a>, and <a class="drug drug_general" data-topicid="114897" href="/d/drug information/114897.html" rel="external">copanlisib</a> [<a href="#rid65">65-69</a>]. While initial studies suggested efficacy, subsequent studies did not confirm a favorable risk to benefit ratio. </p><p>There have been concerns raised about PI3K inhibitors as some trials have shown an increased risk of death due to toxicity. An FDA report described six randomized trials that suggested higher death rates with PI3K inhibitors despite improvement in other efficacy parameters, including response rate and PFS [<a href="#rid68">68</a>]. While there is uncertainty in the OS estimates for each trial given the low number of observed deaths, these data are concerning given the consistency of these observations across multiple trials of different PI3K inhibitors in patients with clinically indolent lymphoid malignancies. Outcomes may be better in centers with extensive experience and resources to detect and manage PI3K-related toxicities.</p><p class="headingAnchor" id="H1649019354"><span class="h2">Chimeric antigen receptor T cells</span><span class="headingEndMark"> — </span>Chimeric antigen receptor (CAR)-T cell therapy is an option for patients with multiply relapsed FL. The use of CAR-T therapy is individualized weighing disease tempo, availability of other treatments, and expected toxicity. Since most patients with relapsed FL have favorable outcomes with other, less toxic treatment options, we generally reserve CAR-T therapy for patients with multiply relapsed FL with short prior remission durations (eg, &lt;24 months). While initial studies suggest that CAR-T therapy has activity against relapsed or refractory FL, the quality of the evidence is low, treatment is associated with substantial toxicity, and the manufacturing process is complex and expensive. </p><p>CAR-T cells are generated from the patient's own T lymphocytes, which are genetically modified (transfected) with a gene that encodes a CAR to direct the patient's T cells against the lymphoma cells. The T cells are genetically modified ex vivo, expanded in a production facility, and then infused back into the patient as therapy. Various CAR-T constructs have subtle structural differences, even when directed against the same antigen, but they have not been directly compared and clinical effects of such differences are not yet clear. </p><p><a class="drug drug_general" data-topicid="115350" href="/d/drug information/115350.html" rel="external">Axicabtagene ciloleucel</a> (axi-cel) and <a class="drug drug_general" data-topicid="114674" href="/d/drug information/114674.html" rel="external">tisagenlecleucel</a> (tisa-cel) are CD19-directed CAR-T immunotherapies that have received accelerated approved by the FDA for treatment of adults with relapsed or refractory FL after two or more lines of systemic therapy. They are available in the United States through a risk evaluation and mitigation strategy (REMS), and the US FDA labels carry warnings for cytokine release syndrome (CRS) and neurologic events. Facilities that dispense these agents require special certification, staff must be trained to recognize and manage adverse events, and <a class="drug drug_general" data-topicid="10208" href="/d/drug information/10208.html" rel="external">tocilizumab</a> (a humanized monoclonal antibody against the interleukin-6 receptor [IL-6R]) must be available for immediate administration.</p><p>Data regarding the use of CAR-T cells in FL comes from single-arm prospective trials with relatively short follow-up [<a href="#rid70">70-72</a>]. Two single-arm, open label multicenter trials evaluated axi-cel (ZUMA-5) and tisa-cel (ELARA) in adults with relapsed or refractory FL after two or more lines of systemic therapy, including a combination of an anti-CD20 monoclonal antibody and an alkylating agent [<a href="#rid72">72,73</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Axi-cel</strong> – Among the 86 patients with FL treated with axi-cel in ZUMA-5, the ORR was 94 percent (79 percent CR, 15 percent PR) with a median time to first response of one month [<a href="#rid73">73</a>]. Response rates were similar in patients with and without high-risk features, including early treatment failure. The median duration of response was not reached with a median follow-up of 23 months. The estimated PFS at 18 months was 73 percent (95% CI 64-80 percent) and estimated OS at 18 months was 92 percent (95% CI 85-95 percent). CRS of any grade was reported in 78 percent (6 percent ≥grade 3). Management included <a class="drug drug_general" data-topicid="10208" href="/d/drug information/10208.html" rel="external">tocilizumab</a> (50 percent), corticosteroids (18 percent), and vasopressors (5 percent). One patient died of multisystem organ failure prior to the resolution of CRS. A second response was attained in all 11 patients with FL retreated with axi-cel at relapse.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Tisa-cel</strong> – Among the 90 patients with FL treated with tisa-cel in ELARA, the ORR was 86 percent (69 percent CR, 17 percent PR) with a median time to first response of 2.9 months [<a href="#rid72">72,74</a>]. The median duration of response was not reached with a median follow-up of 9.1 months. The estimated PFS at 12 months was 71 percent (95% CI 58-80 percent). CRS of any grade was reported in 53 percent, all less than grade 3.</p><p></p><p>Another trial of CAR-T reported that 10 of 14 patients with relapsed/refractory FL attained a CR by three months [<a href="#rid70">70</a>]. Among patients who achieved CR, all but one remained in CR at a median follow-up of two years.</p><p>CAR-T therapy is associated with serious complications, including some fatal neurologic events and CRS, which is a severe systemic response (eg, high fever, flu-like symptoms, hypotension, mental status changes) to the activation and proliferation of CAR-T cells. CRS is observed in nearly all treated patients and may be life-threatening, but it typically responds to treatment with aggressive supportive care that includes <a class="drug drug_general" data-topicid="10208" href="/d/drug information/10208.html" rel="external">tocilizumab</a> and corticosteroids. Neurologic toxicities may also be severe or life-threatening. Other adverse events include hypersensitivity reactions, serious infections, prolonged cytopenias, prolonged hypogammaglobulinemia, and second malignancies. CRS and immune effector cell-associated neurotoxicity syndrome (ICANS) are discussed separately. (See  <a class="medical medical_review" href="/d/html/118012.html" rel="external">"Cytokine release syndrome (CRS)"</a> and  <a class="medical medical_review" href="/d/html/129618.html" rel="external">"Immune effector cell-associated neurotoxicity syndrome (ICANS)"</a>.)</p><p class="headingAnchor" id="H171150611"><span class="h2">Mosunetuzumab</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="140391" href="/d/drug information/140391.html" rel="external">Mosunetuzumab</a> is a bispecific monoclonal antibody directed at both CD20 on FL cells and CD3 on cytotoxic T cells [<a href="#rid75">75</a>]. Mosunetuzumab is approved by the US Food and Drug Administration (FDA) and the European Medicines Agency for adults with relapsed or refractory FL who have received at least two prior systemic therapies [<a href="#rid76">76,77</a>]. Where available, we consider mosunetuzumab an option for patients with multiply relapsed FL with short prior remission durations (eg, &lt;24 months). While initial studies have shown high response rates, mosunetuzumab has not been directly compared with other therapies, and longer follow-up is needed to better understand efficacy and toxicity. </p><p><a class="drug drug_general" data-topicid="140391" href="/d/drug information/140391.html" rel="external">Mosunetuzumab</a> is administered intravenously. Following an initial step-up dosing schedule, the drug is administered once every 21 days. Those who achieve a CR receive 8 total cycles, whereas those with a PR or stable disease receive up to 17 cycles. The package insert carries warnings of CRS, serious infection, tumor flare, tumor lysis syndrome, and the need to avoid live and/or live-attenuated vaccines [<a href="#rid76">76,77</a>]. Facilities that dispense mosunetuzumab must be specially qualified and have appropriate medical support to manage severe reactions such as CRS.</p><p>Data regarding the efficacy and safety of <a class="drug drug_general" data-topicid="140391" href="/d/drug information/140391.html" rel="external">mosunetuzumab</a> in FL come from a single-arm, multicenter phase 2 study of 90 patients with relapsed or refractory FL who had received at least two prior lines of treatment (median three), including an anti-CD20 therapy and an alkylating agent [<a href="#rid78">78</a>]. Approximately half had progression within 24 months of initial therapy and 21 percent had prior autologous HCT. </p><p>The ORR was 80 percent with 60 percent CR and 20 percent PR; at a median follow-up of 18 months, median duration of response was 23 months and median PFS was 18 months. The CR rate compared favorably to that seen in a historical control group treated with <a class="drug drug_general" data-topicid="114897" href="/d/drug information/114897.html" rel="external">copanlisib</a> (60 versus 14 percent). </p><p>The most common adverse events were CRS (44 percent), fatigue (37 percent), and headache (31 percent). CRS was predominantly grade 1 or 2 and confined to the first cycle. The most common grade 3 or 4 adverse events were decreased neutrophil count (27 percent), hypophosphatemia (17 percent), hyperglycemia (8 percent), and anemia (8 percent).</p><p class="headingAnchor" id="H549037257"><span class="h2">Transplantation</span><span class="headingEndMark"> — </span>We offer high dose chemotherapy with autologous HCT (hematologic rescue) to fit patients who attain a CR following treatment of multiply relapsed disease  (<a class="graphic graphic_algorithm graphicRef119214" href="/d/graphic/119214.html" rel="external">algorithm 1</a>), and to patients who attain a CR following treatment of early treatment failure. CAR-T therapy is an alternative for young, fit patients, and has largely supplanted allogeneic HCT in this setting. (See <a class="local">'Chimeric antigen receptor T cells'</a> above.)</p><p>Both high dose chemotherapy with autologous HCT (hematologic rescue) and nonmyeloablative or reduced intensity allogeneic HCT have been used for the treatment of FL. (See  <a class="medical medical_review" href="/d/html/4709.html" rel="external">"Autologous hematopoietic cell transplantation in follicular lymphoma", section on 'Relapsed disease'</a> and  <a class="medical medical_review" href="/d/html/88808.html" rel="external">"Allogeneic hematopoietic cell transplantation in follicular lymphoma", section on 'Nonmyeloablative and reduced intensity HCT'</a>.)</p><p>Both autologous HCT and allogeneic HCT appear to have a survival benefit for the treatment of relapsed FL, but differing risks:</p><p class="bulletIndent1"><span class="glyph">●</span>There is a clear increase in toxicity (ie, short-term treatment-related mortality plus the risk of secondary malignancy) when comparing conventional therapy with autologous HCT and allogeneic HCT, with an approximate risk of treatment-related mortality of &lt;5 percent with conventional therapy (ie, no HCT), 5 to 20 percent with autologous HCT, and 10 to 30 percent with allogeneic HCT.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Although there is shorter follow-up for series of patients who have undergone allogeneic HCT, there appears to be a parallel increase in efficacy, with a chance of possible long-term disease-free remission ranging from zero percent with conventional therapy, 25 to 40 percent with autologous HCT, and 40 to 60 percent with allogeneic HCT.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>It is possible that the incremental benefit in each case outweighs the incremental toxicity. Indeed, the results of autologous HCT seem superior to those of salvage chemotherapy alone. (See  <a class="medical medical_review" href="/d/html/4709.html" rel="external">"Autologous hematopoietic cell transplantation in follicular lymphoma", section on 'Relapsed disease'</a>.)</p><p></p><p>A comparison of nonrandomized trials of these different procedures is limited by the use of different patient selection criteria for the different regimens [<a href="#rid79">79</a>]. Unfortunately, a randomized trial is difficult to perform in this circumstance. A multicenter trial comparing allogeneic to autologous transplantation was closed early due to poor accrual (NCT00096460).</p><p>Small case series have suggested a benefit of allogeneic HCT over autologous HCT [<a href="#rid80">80-82</a>]. Large registry-based analyses have illustrated the decreased relapse rate and increased short-term treatment-related mortality with allogeneic HCT [<a href="#rid43">43,83-86</a>].</p><p>One of the largest of these reported the outcomes of 518 adults with relapsed or refractory FL following initial rituximab-based therapy who underwent reduced intensity allogeneic HCT or autologous HCT between 2000 and 2012 [<a href="#rid86">86</a>]. The patients undergoing allogeneic HCT were younger and more heavily pretreated and were more likely to have advanced stage disease and chemotherapy resistance. When compared with allogeneic HCT, autologous HCT was associated with the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Lower nonrelapse mortality (5 versus 26 percent at five years)</p><p class="bulletIndent1"><span class="glyph">●</span>Higher rates of relapse/progression (54 versus 20 percent at five years)</p><p class="bulletIndent1"><span class="glyph">●</span>Inferior PFS (41 versus 58 percent at five years)</p><p class="bulletIndent1"><span class="glyph">●</span>Superior OS in the first 24 months (RR 0.41) </p><p class="bulletIndent1"><span class="glyph">●</span>Inferior survival beyond 24 months (RR 2.2)</p><p class="bulletIndent1"><span class="glyph">●</span>A higher incidence of second hematologic malignancies (7 versus 0 percent at 10 years)</p><p></p><p>These results are consistent with those seen in other trials. Even in highly selected patients, approximately one-quarter of patients undergoing reduced intensity allogeneic HCT will die of complications of the therapy. However, these deaths usually occur early in the post-transplant period. For those that survive past two years, PFS and OS are better than those seen with autologous HCT. While patients undergoing allogeneic HCT have a lower relapse rate, there is a continued risk of death due to late toxicities from graft-versus-host disease [<a href="#rid85">85</a>].</p><p class="headingAnchor" id="H194741002"><span class="h2">Radiation for palliation</span><span class="headingEndMark"> — </span>Radiation therapy (RT) is primarily used for the palliation of patients who have symptoms related to a single disease site. FL is responsive to RT; low dose RT (eg, total dose of 4 Gy) can be used for the palliation of patients who have symptoms related to a single disease site [<a href="#rid87">87-90</a>].</p><p class="headingAnchor" id="H4218911488"><span class="h2">Radioimmunotherapy</span><span class="headingEndMark"> — </span>Radioimmunotherapy (RIT) uses monoclonal antibodies linked to radioisotopes. <a class="drug drug_general" data-topicid="8709" href="/d/drug information/8709.html" rel="external">Ibritumomab tiuxetan</a> is a murine anti-CD20 monoclonal antibody conjugated to the radioisotope yttrium-90 that is approved by the US Food and Drug Administration for the treatment of patients with relapsed or refractory FL, including patients with rituximab-refractory FL. While RIT is an effective treatment alternative for eligible patients, it is not commonly employed due to the complexity of administration.</p><p>Prospective trials of RIT demonstrate response rates of 60 to 80 percent in previously treated disease [<a href="#rid91">91-96</a>]. Median PFS is less than one year, but patients who achieve a CR have a median time to progression of close to four years.</p><p>The most profound side effects of RIT are potentially prolonged and significant cytopenias with cell count nadirs ranging from four to nine weeks post-therapy with recovery one to four weeks post-nadir. The most common cytopenias are leukopenia and thrombocytopenia, which are easily managed in the majority of patients. RIT causes a transient depletion of B cells for approximately six to nine months but has not been associated with significant increases in severe infections or hospitalizations. RIT can be associated with an infusion reaction similar to that seen with other monoclonal antibodies. This is described in more detail separately. (See  <a class="medical medical_review" href="/d/html/2811.html" rel="external">"Infusion-related reactions to therapeutic monoclonal antibodies used for cancer therapy", section on 'Ibritumomab'</a>.)</p><p>Initial reports suggested a possible risk of treatment-related myelodysplastic syndrome (t-MDS) and acute myeloid leukemia (t-AML). Although the rate of t-MDS and t-AML does not appear to be increased in subsequent reports, controversy regarding this potential risk remains [<a href="#rid97">97-101</a>]. Early evidence suggests that patients relapsing following treatment with RIT may tolerate other treatment approaches including chemotherapy, external beam radiation therapy, and autologous HCT [<a href="#rid102">102-104</a>].</p><p class="headingAnchor" id="H31594822"><span class="h1">CLINICAL TRIALS</span><span class="headingEndMark"> — </span>Often there is no better therapy to offer a patient than enrollment onto a well-designed, scientifically valid, peer-reviewed clinical trial. Additional information and instructions for referring a patient to an appropriate research center can be obtained from the United States National Institutes of Health (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.clinicaltrials.gov%2F&amp;token=Rti1NBSWdX%2F%2FH%2FlCKGrzlGu03gYcMJXuTK3xOgZRWSzRV8srxVomMWotD038y2Xv&amp;TOPIC_ID=4755" target="_blank">www.clinicaltrials.gov</a>).</p><p>Many agents are under active investigation. These include combinations of agents already used in FL, agents approved for other diseases, new antibodies (eg, <a class="drug drug_general" data-topicid="98582" href="/d/drug information/98582.html" rel="external">blinatumomab</a>, antibody-drug conjugates [<a href="#rid105">105</a>], bispecific antibodies [<a href="#rid106">106,107</a>], anti-PD1 immune checkpoint inhibitors [<a href="#rid108">108</a>], anti-CD47 macrophage immune checkpoint inhibitors [<a href="#rid109">109</a>]), and other novel agents (eg, Bruton tyrosine kinase inhibitors [<a href="#rid62">62,63</a>] and <a class="drug drug_general" data-topicid="121575" href="/d/drug information/121575.html" rel="external">polatuzumab vedotin</a>).</p><p class="headingAnchor" id="H2318906105"><span class="h1">RESPONSE EVALUATION AND SURVEILLANCE FOR RELAPSE</span><span class="headingEndMark"> — </span>The assessment of disease response to therapy and surveillance for relapse is similar to that used following initial therapy. This is described in more detail separately. (See  <a class="medical medical_review" href="/d/html/4741.html" rel="external">"Initial treatment of stage I follicular lymphoma", section on 'Evaluation of response to therapy'</a> and  <a class="medical medical_review" href="/d/html/4741.html" rel="external">"Initial treatment of stage I follicular lymphoma", section on 'Surveillance for relapse'</a>.)</p><p class="headingAnchor" id="H2144234726"><span class="h1">SPECIAL CONSIDERATIONS DURING THE COVID-19 PANDEMIC</span><span class="headingEndMark"> — </span>The coronavirus disease 2019 (COVID-19) pandemic has increased the complexity of cancer care, both in regard to minimizing the risk of transmission and in coordinating the timing of cancer treatments. Further details are discussed separately. (See  <a class="medical medical_review" href="/d/html/128993.html" rel="external">"COVID-19: Considerations in patients with cancer"</a>.)</p><p class="headingAnchor" id="H2006550977"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/133193.html" rel="external">"Society guideline links: Management of follicular lymphoma"</a>.)</p><p class="headingAnchor" id="H29042731"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient education" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/d/html/15857.html" rel="external">"Patient education: Follicular lymphoma (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/d/html/694.html" rel="external">"Patient education: Follicular lymphoma in adults (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H22"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Rule out histologic transformation</strong> – For patients with suspected relapse of follicular lymphoma (FL), we have a low threshold to biopsy prior to retreatment to confirm relapse and evaluate for histologic transformation. (See <a class="local">'Rule out histologic transformation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Recognize early treatment failure</strong> – Most patients have a clinically indolent, relapsing course with survival rates that mirror the general population. Approximately 20 percent have an aggressive course with short remission durations, frequent relapses, and shortened survival. </p><p></p><p class="bulletIndent1">These aggressive cases can be identified by "early treatment failure," such as progression within 24 months of initial treatment with BR (<a class="drug drug_general" data-topicid="9323" href="/d/drug information/9323.html" rel="external">bendamustine</a> plus <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a>), R-CHOP (<a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a>, <a class="drug drug_general" data-topicid="9391" href="/d/drug information/9391.html" rel="external">doxorubicin</a>, <a class="drug drug_general" data-topicid="10045" href="/d/drug information/10045.html" rel="external">vincristine</a>, and <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> plus rituximab), or R-CVP (cyclophosphamide, vincristine, and prednisone plus rituximab), or within 12 months of single-agent rituximab. (See <a class="local">'Recognize early treatment failure'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management</strong> – Patients with asymptomatic recurrent FL do not necessarily require immediate treatment but should be followed closely for the development of symptomatic disease. Patients with symptomatic FL or an increase in disease tempo require treatment. (See <a class="local">'Indications for treatment'</a> above.)</p><p></p><p class="bulletIndent1">There is no standard therapy for FL and practice varies; patients should be encouraged to participate in clinical trials. We use a risk-stratified approach, which considers the timing of relapse and results from <em>EZH2</em> mutation testing  (<a class="graphic graphic_algorithm graphicRef119214" href="/d/graphic/119214.html" rel="external">algorithm 1</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Late relapse</strong> – For most patients with late relapse, we offer an anti-CD20 monoclonal antibody (<a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> or <a class="drug drug_general" data-topicid="91388" href="/d/drug information/91388.html" rel="external">obinutuzumab</a>), either alone or in combination with chemotherapy or <a class="drug drug_general" data-topicid="9822" href="/d/drug information/9822.html" rel="external">lenalidomide</a>, as follows. (See <a class="local">'Immunotherapy-based treatment'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with a poor performance status and/or a clinically indolent course, we suggest single-agent <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> for its relatively low toxicity profile (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Single-agent rituximab versus obinutuzumab or ofatumumab'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with a good performance status, we suggest <a class="drug drug_general" data-topicid="91388" href="/d/drug information/91388.html" rel="external">obinutuzumab</a> plus combination chemotherapy or <a class="drug drug_general" data-topicid="9822" href="/d/drug information/9822.html" rel="external">lenalidomide</a> rather than rituximab-based combinations for its superior response rates despite greater toxicity and no proven improvement in survival rates (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Chemoimmunotherapy'</a> above.)</p><p></p><p class="bulletIndent2">We offer O-CHOP or <a class="drug drug_general" data-topicid="9822" href="/d/drug information/9822.html" rel="external">lenalidomide</a> plus <a class="drug drug_general" data-topicid="91388" href="/d/drug information/91388.html" rel="external">obinutuzumab</a> to those relapsing after bendamustine-based regimens. We offer <a class="drug drug_general" data-topicid="9323" href="/d/drug information/9323.html" rel="external">bendamustine</a> plus obinutuzumab or lenalidomide plus obinutuzumab to those relapsing after CHOP-based regimens.</p><p></p><p class="bulletIndent2">Our contributors differ in their use of maintenance therapy. (See <a class="local">'Use of maintenance'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>We offer the EZH2 inhibitor <a class="drug drug_general" data-topicid="126937" href="/d/drug information/126937.html" rel="external">tazemetostat</a> in late first relapse to the approximately 20 percent of patients with <em>EZH2</em> mutation, and we reserve it for subsequent relapse in patients without <em>EZH2</em> mutation. (See <a class="local">'Tazemetostat'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Early relapse</strong> – For patients with early treatment failure, our approach depends on candidacy for high dose chemotherapy and autologous hematopoietic cell transplantation (HCT) rescue:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patents who are eligible for HCT, we suggest chemoimmunotherapy with O-CHOP or <a class="drug drug_general" data-topicid="9323" href="/d/drug information/9323.html" rel="external">bendamustine</a> plus <a class="drug drug_general" data-topicid="91388" href="/d/drug information/91388.html" rel="external">obinutuzumab</a> rather than less intensive therapies with the goal of attaining a complete remission (CR) (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). </p><p></p><p class="bulletIndent2">Those who attain a CR may proceed to HCT in an attempt to attain long-term remission. Patients with early treatment failure after single-agent <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> who achieve CR with chemoimmunotherapy may reasonably defer HCT until subsequent relapse. </p><p></p><p class="bulletIndent2">For those who are unable to achieve CR, options include serial novel agents (eg, <a class="drug drug_general" data-topicid="9822" href="/d/drug information/9822.html" rel="external">lenalidomide</a>, <a class="drug drug_general" data-topicid="126937" href="/d/drug information/126937.html" rel="external">tazemetostat</a>) with a plan for autologous HCT in CR or chimeric antigen receptor T cell (CAR-T) therapy. (See <a class="local">'Therapeutic strategy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients who are ineligible for HCT or CAR-T, or do not wish to undergo these procedures, we suggest treatment with serial novel agents rather than chemoimmunotherapy (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). This preference is based on short-term follow-up of trials that suggest these novel agents are effective in this setting and an understanding that responses to chemoimmunotherapy are likely to be short-lived.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Subsequent relapse</strong> – Novel agents are used for multiply relapsed FL. A choice is made based on the patient's prior treatment, the regimens' expected toxicities, route of administration, and the clinician's experience with the regimens. Fit patients who attain a CR may proceed with autologous HCT or CAR-T in an attempt to attain long-term remission. (See <a class="local">'Multiply relapsed disease'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Casulo C, Byrtek M, Dawson KL, et al. Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study. J Clin Oncol 2015; 33:2516.</a></li><li><a class="nounderline abstract_t">Maurer MJ, Bachy E, Ghesquières H, et al. Early event status informs subsequent outcome in newly diagnosed follicular lymphoma. Am J Hematol 2016; 91:1096.</a></li><li><a class="nounderline abstract_t">Sarkozy C, Trneny M, Xerri L, et al. Risk Factors and Outcomes for Patients With Follicular Lymphoma Who Had Histologic Transformation After Response to First-Line Immunochemotherapy in the PRIMA Trial. J Clin Oncol 2016; 34:2575.</a></li><li><a class="nounderline abstract_t">Weisdorf DJ, Andersen JW, Glick JH, Oken MM. Survival after relapse of low-grade non-Hodgkin's lymphoma: implications for marrow transplantation. J Clin Oncol 1992; 10:942.</a></li><li><a class="nounderline abstract_t">Lockmer S, Østenstad B, Hagberg H, et al. Chemotherapy-Free Initial Treatment of Advanced Indolent Lymphoma Has Durable Effect With Low Toxicity: Results From Two Nordic Lymphoma Group Trials With More Than 10 Years of Follow-Up. J Clin Oncol 2018; :JCO1800262.</a></li><li><a class="nounderline abstract_t">Sarkozy C, Maurer MJ, Link BK, et al. Cause of Death in Follicular Lymphoma in the First Decade of the Rituximab Era: A Pooled Analysis of French and US Cohorts. J Clin Oncol 2019; 37:144.</a></li><li><a class="nounderline abstract_t">Magnano L, Alonso-Alvarez S, Alcoceba M, et al. Life expectancy of follicular lymphoma patients in complete response at 30 months is similar to that of the Spanish general population. Br J Haematol 2019; 185:480.</a></li><li><a class="nounderline abstract_t">Seymour JF, Marcus R, Davies A, et al. Association of early disease progression and very poor survival in the GALLIUM study in follicular lymphoma: benefit of obinutuzumab in reducing the rate of early progression. Haematologica 2019; 104:1202.</a></li><li><a class="nounderline abstract_t">Moccia AA, Schär S, Hayoz S, et al. Prognostic value of POD24 validation in follicular lymphoma patients initially treated with chemotherapy-free regimens in a pooled analysis of three randomized trials of the Swiss Group for Clinical Cancer Research (SAKK). Br J Haematol 2021; 192:1031.</a></li><li><a class="nounderline abstract_t">Bachy E, Cerhan JR, Salles G. Early progression of disease in follicular lymphoma is a robust correlate but not a surrogate for overall survival. Blood Adv 2021; 5:1729.</a></li><li><a class="nounderline abstract_t">Weibull CE, Wästerlid T, Wahlin BE, et al. Survival by First-line Treatment Type and Timing of Progression Among Follicular Lymphoma Patients: A National Population-based Study in Sweden. Hemasphere 2023; 7:e838.</a></li><li><a class="nounderline abstract_t">Casulo C, Dixon JG, Le-Rademacher J, et al. Validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients on 13 clinical trials. Blood 2022; 139:1684.</a></li><li><a class="nounderline abstract_t">Freeman CL, Kridel R, Moccia AA, et al. Early progression after bendamustine-rituximab is associated with high risk of transformation in advanced stage follicular lymphoma. Blood 2019; 134:761.</a></li><li><a class="nounderline abstract_t">Kahl BS, Hong F, Williams ME, et al. Rituximab extended schedule or re-treatment trial for low-tumor burden follicular lymphoma: eastern cooperative oncology group protocol e4402. J Clin Oncol 2014; 32:3096.</a></li><li><a class="nounderline abstract_t">Ghielmini M, Schmitz SF, Cogliatti SB, et al. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule. Blood 2004; 103:4416.</a></li><li><a class="nounderline abstract_t">Martinelli G, Schmitz SF, Utiger U, et al. Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98. J Clin Oncol 2010; 28:4480.</a></li><li class="breakAll">Rituximab and hyaluronidase human injection. United States prescribing information. Revised June 2017. US Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761064s000lbl.pdf (Accessed on June 23, 2017).</li><li><a class="nounderline abstract_t">Maloney DG, Ogura M, Fukuhara N, et al. A phase 3 randomized study (HOMER) of ofatumumab vs rituximab in iNHL relapsed after rituximab-containing therapy. Blood Adv 2020; 4:3886.</a></li><li><a class="nounderline abstract_t">Sehn LH, Goy A, Offner FC, et al. Randomized Phase II Trial Comparing Obinutuzumab (GA101) With Rituximab in Patients With Relapsed CD20+ Indolent B-Cell Non-Hodgkin Lymphoma: Final Analysis of the GAUSS Study. J Clin Oncol 2015; 33:3467.</a></li><li><a class="nounderline abstract_t">Davis TA, Grillo-López AJ, White CA, et al. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. J Clin Oncol 2000; 18:3135.</a></li><li><a class="nounderline abstract_t">Schulz H, Bohlius JF, Trelle S, et al. Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. J Natl Cancer Inst 2007; 99:706.</a></li><li><a class="nounderline abstract_t">Marcus R, Davies A, Ando K, et al. Obinutuzumab for the First-Line Treatment of Follicular Lymphoma. N Engl J Med 2017; 377:1331.</a></li><li><a class="nounderline abstract_t">Sehn LH, Chua N, Mayer J, et al. Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial. Lancet Oncol 2016; 17:1081.</a></li><li><a class="nounderline abstract_t">Cheson BD, Chua N, Mayer J, et al. Overall Survival Benefit in Patients With Rituximab-Refractory Indolent Non-Hodgkin Lymphoma Who Received Obinutuzumab Plus Bendamustine Induction and Obinutuzumab Maintenance in the GADOLIN Study. J Clin Oncol 2018; 36:2259.</a></li><li><a class="nounderline abstract_t">Rummel MJ, Janssens A, MacDonald D, et al. A phase 3, randomized study of ofatumumab combined with bendamustine in rituximab-refractory iNHL (COMPLEMENT A + B study). Br J Haematol 2021; 193:1123.</a></li><li><a class="nounderline abstract_t">Hiddemann W, Barbui AM, Canales MA, et al. Immunochemotherapy With Obinutuzumab or Rituximab for Previously Untreated Follicular Lymphoma in the GALLIUM Study: Influence of Chemotherapy on Efficacy and Safety. J Clin Oncol 2018; 36:2395.</a></li><li><a class="nounderline abstract_t">Fung M, Jacobsen E, Freedman A, et al. Increased Risk of Infectious Complications in Older Patients With Indolent Non-Hodgkin Lymphoma Exposed to Bendamustine. Clin Infect Dis 2019; 68:247.</a></li><li><a class="nounderline abstract_t">Rummel MJ, Al-Batran SE, Kim SZ, et al. Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma. J Clin Oncol 2005; 23:3383.</a></li><li><a class="nounderline abstract_t">Robinson KS, Williams ME, van der Jagt RH, et al. Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma. J Clin Oncol 2008; 26:4473.</a></li><li><a class="nounderline abstract_t">Rummel M, Kaiser U, Balser C, et al. Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial. Lancet Oncol 2016; 17:57.</a></li><li><a class="nounderline abstract_t">van Oers MH, Klasa R, Marcus RE, et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood 2006; 108:3295.</a></li><li><a class="nounderline abstract_t">van Oers MH, Van Glabbeke M, Giurgea L, et al. Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study. J Clin Oncol 2010; 28:2853.</a></li><li><a class="nounderline abstract_t">Radford J, Davies A, Cartron G, et al. Obinutuzumab (GA101) plus CHOP or FC in relapsed/refractory follicular lymphoma: results of the GAUDI study (BO21000). Blood 2013; 122:1137.</a></li><li><a class="nounderline abstract_t">Barr PM, Li H, Burack WR, et al. R-CHOP, radioimmunotherapy, and maintenance rituximab in untreated follicular lymphoma (SWOG S0801): a single-arm, phase 2, multicentre study. Lancet Haematol 2018; 5:e102.</a></li><li><a class="nounderline abstract_t">Rummel MJ, Buske C, Hertenstein B, et al. Four Versus Two Years of Rituximab Maintenance (R-maintenance) Following Bendamustine Plus Rituximab (B-R): Initial Results of a Prospective, Randomized Multicenter Phase 3 Study in First-Line Follicular Lymphoma (the StiL NHL7-2008 MAINTAIN study) (abstract 483). Blood 2017.</a></li><li><a class="nounderline abstract_t">Vidal L, Gafter-Gvili A, Salles G, et al. Rituximab maintenance for the treatment of patients with follicular lymphoma: an updated systematic review and meta-analysis of randomized trials. J Natl Cancer Inst 2011; 103:1799.</a></li><li class="breakAll">Obinutuzumab injection. United States Prescribing Information. US National Library of Medicine. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125486s033lbl.pdf (Accessed on July 20, 2022).</li><li><a class="nounderline abstract_t">Davies A, Merli F, Mihaljevic B, et al. Pharmacokinetics and safety of subcutaneous rituximab in follicular lymphoma (SABRINA): stage 1 analysis of a randomised phase 3 study. Lancet Oncol 2014; 15:343.</a></li><li><a class="nounderline abstract_t">Davies A, Merli F, Mihaljević B, et al. Efficacy and safety of subcutaneous rituximab versus intravenous rituximab for first-line treatment of follicular lymphoma (SABRINA): a randomised, open-label, phase 3 trial. Lancet Haematol 2017; 4:e272.</a></li><li><a class="nounderline abstract_t">Rummel M, Kim TM, Aversa F, et al. Preference for subcutaneous or intravenous administration of rituximab among patients with untreated CD20+ diffuse large B-cell lymphoma or follicular lymphoma: results from a prospective, randomized, open-label, crossover study (PrefMab). Ann Oncol 2017; 28:836.</a></li><li><a class="nounderline abstract_t">Assouline S, Buccheri V, Delmer A, et al. Pharmacokinetics, safety, and efficacy of subcutaneous versus intravenous rituximab plus chemotherapy as treatment for chronic lymphocytic leukaemia (SAWYER): a phase 1b, open-label, randomised controlled non-inferiority trial. Lancet Haematol 2016; 3:e128.</a></li><li><a class="nounderline abstract_t">Link BK, Day BM, Zhou X, et al. Second-line and subsequent therapy and outcomes for follicular lymphoma in the United States: data from the observational National LymphoCare Study. Br J Haematol 2019; 184:660.</a></li><li><a class="nounderline abstract_t">Smith SM, Godfrey J, Ahn KW, et al. Autologous transplantation versus allogeneic transplantation in patients with follicular lymphoma experiencing early treatment failure. Cancer 2018; 124:2541.</a></li><li><a class="nounderline abstract_t">Casulo C, Friedberg JW, Ahn KW, et al. Autologous Transplantation in Follicular Lymphoma with Early Therapy Failure: A National LymphoCare Study and Center for International Blood and Marrow Transplant Research Analysis. Biol Blood Marrow Transplant 2018; 24:1163.</a></li><li><a class="nounderline abstract_t">Manna M, Lee-Ying R, Davies G, et al. Autologous transplantation improves survival rates for follicular lymphoma patients who relapse within two years of chemoimmunotherapy: a multi-center retrospective analysis of consecutively treated patients in the real world. Leuk Lymphoma 2019; 60:133.</a></li><li><a class="nounderline abstract_t">Jiménez-Ubieto A, Grande C, Caballero D, et al. Autologous stem cell transplantation may be curative for patients with follicular lymphoma with early therapy failure who reach complete response after rescue treatment. Hematol Oncol 2018; 36:765.</a></li><li><a class="nounderline abstract_t">Jurinovic V, Metzner B, Pfreundschuh M, et al. Autologous Stem Cell Transplantation for Patients with Early Progression of Follicular Lymphoma: A Follow-Up Study of 2 Randomized Trials from the German Low Grade Lymphoma Study Group. Biol Blood Marrow Transplant 2018; 24:1172.</a></li><li><a class="nounderline abstract_t">Rivas-Delgado A, Magnano L, Moreno-Velázquez M, et al. Response duration and survival shorten after each relapse in patients with follicular lymphoma treated in the rituximab era. Br J Haematol 2019; 184:753.</a></li><li><a class="nounderline abstract_t">Batlevi CL, Sha F, Alperovich A, et al. Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups. Blood Cancer J 2020; 10:74.</a></li><li><a class="nounderline abstract_t">Yamshon S, Christos PJ, Demetres M, et al. Venous thromboembolism in patients with B-cell non-Hodgkin lymphoma treated with lenalidomide: a systematic review and meta-analysis. Blood Adv 2018; 2:1429.</a></li><li><a class="nounderline abstract_t">Leonard JP, Trneny M, Izutsu K, et al. AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma. J Clin Oncol 2019; 37:1188.</a></li><li><a class="nounderline abstract_t">Leonard JP, Jung SH, Johnson J, et al. Randomized Trial of Lenalidomide Alone Versus Lenalidomide Plus Rituximab in Patients With Recurrent Follicular Lymphoma: CALGB 50401 (Alliance). J Clin Oncol 2015; 33:3635.</a></li><li><a class="nounderline abstract_t">Morschhauser F, Salles G, Le Gouill S, et al. An open-label phase 1b study of obinutuzumab plus lenalidomide in relapsed/refractory follicular B-cell lymphoma. Blood 2018; 132:1486.</a></li><li class="breakAll">Tazemetostat tablets. United States prescribing information. Revised June 2020. US Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf (Accessed on June 18, 2020).</li><li><a class="nounderline abstract_t">Italiano A, Soria JC, Toulmonde M, et al. Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study. Lancet Oncol 2018; 19:649.</a></li><li><a class="nounderline abstract_t">Morschhauser F, Tilly H, Chaidos A, et al. Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial. Lancet Oncol 2020; 21:1433.</a></li><li><a class="nounderline abstract_t">Pastore A, Jurinovic V, Kridel R, et al. Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry. Lancet Oncol 2015; 16:1111.</a></li><li><a class="nounderline abstract_t">Armand P, Janssens A, Gritti G, et al. Efficacy and safety results from CheckMate 140, a phase 2 study of nivolumab for relapsed/refractory follicular lymphoma. Blood 2021; 137:637.</a></li><li><a class="nounderline abstract_t">Gopal AK, Schuster SJ, Fowler NH, et al. Ibrutinib as Treatment for Patients With Relapsed/Refractory Follicular Lymphoma: Results From the Open-Label, Multicenter, Phase II DAWN Study. J Clin Oncol 2018; 36:2405.</a></li><li><a class="nounderline abstract_t">Bartlett NL, Costello BA, LaPlant BR, et al. Single-agent ibrutinib in relapsed or refractory follicular lymphoma: a phase 2 consortium trial. Blood 2018; 131:182.</a></li><li><a class="nounderline abstract_t">Zinzani PL, Flinn IW, Yuen SLS, et al. Venetoclax-rituximab with or without bendamustine vs bendamustine-rituximab in relapsed/refractory follicular lymphoma. Blood 2020; 136:2628.</a></li><li><a class="nounderline abstract_t">Tam CS, Quach H, Nicol A, et al. Zanubrutinib (BGB-3111) plus obinutuzumab in patients with chronic lymphocytic leukemia and follicular lymphoma. Blood Adv 2020; 4:4802.</a></li><li><a class="nounderline abstract_t">Phillips T, Chan H, Tam CS, et al. Zanubrutinib monotherapy in relapsed/refractory indolent non-Hodgkin lymphoma. Blood Adv 2022; 6:3472.</a></li><li><a class="nounderline abstract_t">Zinzani PL, Mayer J, Flowers CR, et al. ROSEWOOD: A Phase II Randomized Study of Zanubrutinib Plus Obinutuzumab Versus Obinutuzumab Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma. J Clin Oncol 2023; 41:5107.</a></li><li class="breakAll">https://www.fda.gov/drugs/resources-information-approved-drugs/withdrawn-cancer-accelerated-approvals (Accessed on April 22, 2022).</li><li><a class="nounderline abstract_t">Richardson NC, Kasamon Y, Pazdur R, Gormley N. The saga of PI3K inhibitors in haematological malignancies: survival is the ultimate safety endpoint. Lancet Oncol 2022; 23:563.</a></li><li class="breakAll">https://ir.tgtherapeutics.com/news-releases/news-release-details/tg-therapeutics-announces-voluntary-withdrawal-blasnda-u2-treat (Accessed on April 22, 2022).</li><li class="breakAll">https://www.fda.gov/media/157762/download (Accessed on April 25, 2022).</li><li class="breakAll">Bayer provides update on Aliqopa® (copanlisib). Bayer Corporation, 2023. Available at: https://www.bayer.com/en/us/news-stories/update-on-aliqopar (Accessed on November 27, 2023).</li><li><a class="nounderline abstract_t">Schuster SJ, Svoboda J, Chong EA, et al. Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas. N Engl J Med 2017; 377:2545.</a></li><li><a class="nounderline abstract_t">Hirayama AV, Gauthier J, Hay KA, et al. High rate of durable complete remission in follicular lymphoma after CD19 CAR-T cell immunotherapy. Blood 2019; 134:636.</a></li><li><a class="nounderline abstract_t">Fowler NH, Dickinson M, Dreyling M, et al. Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial. Nat Med 2022; 28:325.</a></li><li><a class="nounderline abstract_t">Jacobson CA, Chavez JC, Sehgal AR, et al. Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial. Lancet Oncol 2022; 23:91.</a></li><li class="breakAll">Tisagenlecleucel injection, suspension, prescribing information. DailyMed. Available at: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aad3ba54-dfd3-4cb3-9e2b-c5ef89559189 (Accessed on June 03, 2022).</li><li><a class="nounderline abstract_t">Budde LE, Assouline S, Sehn LH, et al. Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study. J Clin Oncol 2022; 40:481.</a></li><li class="breakAll">Mosunetuzumab product information. https://www.ema.europa.eu/en/documents/product-information/lunsumio-epar-product-information_en.pdf (Accessed on August 05, 2022).</li><li class="breakAll">Mosunetuzumab-axgb injection, for intravenous use. United States prescribing information. Revised December 2022. US Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761263s000lbl.pdf (Accessed on January 03, 2023).</li><li><a class="nounderline abstract_t">Budde LE, Sehn LH, Matasar M, et al. Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study. Lancet Oncol 2022; 23:1055.</a></li><li><a class="nounderline abstract_t">Oliansky DM, Gordon LI, King J, et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of follicular lymphoma: an evidence-based review. Biol Blood Marrow Transplant 2010; 16:443.</a></li><li><a class="nounderline abstract_t">Ingram W, Devereux S, Das-Gupta EP, et al. Outcome of BEAM-autologous and BEAM-alemtuzumab allogeneic transplantation in relapsed advanced stage follicular lymphoma. Br J Haematol 2008; 141:235.</a></li><li><a class="nounderline abstract_t">Hosing C, Saliba RM, McLaughlin P, et al. Long-term results favor allogeneic over autologous hematopoietic stem cell transplantation in patients with refractory or recurrent indolent non-Hodgkin's lymphoma. Ann Oncol 2003; 14:737.</a></li><li><a class="nounderline abstract_t">Khouri IF, Milton DR, Gulbis AM, et al. Nine-Year Follow-up of Patients with Relapsed Follicular Lymphoma after Nonmyeloablative Allogeneic Stem Cell Transplant and Autologous Transplant. Clin Cancer Res 2021; 27:5847.</a></li><li><a class="nounderline abstract_t">van Besien K, Loberiza FR Jr, Bajorunaite R, et al. Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma. Blood 2003; 102:3521.</a></li><li><a class="nounderline abstract_t">Robinson SP, Canals C, Luang JJ, et al. The outcome of reduced intensity allogeneic stem cell transplantation and autologous stem cell transplantation when performed as a first transplant strategy in relapsed follicular lymphoma: an analysis from the Lymphoma Working Party of the EBMT. Bone Marrow Transplant 2013; 48:1409.</a></li><li><a class="nounderline abstract_t">Evens AM, Vanderplas A, LaCasce AS, et al. Stem cell transplantation for follicular lymphoma relapsed/refractory after prior rituximab: a comprehensive analysis from the NCCN lymphoma outcomes project. Cancer 2013; 119:3662.</a></li><li><a class="nounderline abstract_t">Klyuchnikov E, Bacher U, Kröger NM, et al. Reduced-Intensity Allografting as First Transplantation Approach in Relapsed/Refractory Grades One and Two Follicular Lymphoma Provides Improved Outcomes in Long-Term Survivors. Biol Blood Marrow Transplant 2015; 21:2091.</a></li><li><a class="nounderline abstract_t">Ganem G, Cartron G, Girinsky T, et al. Localized low-dose radiotherapy for follicular lymphoma: history, clinical results, mechanisms of action, and future outlooks. Int J Radiat Oncol Biol Phys 2010; 78:975.</a></li><li><a class="nounderline abstract_t">Rossier C, Schick U, Miralbell R, et al. Low-dose radiotherapy in indolent lymphoma. Int J Radiat Oncol Biol Phys 2011; 81:e1.</a></li><li><a class="nounderline abstract_t">Chan EK, Fung S, Gospodarowicz M, et al. Palliation by low-dose local radiation therapy for indolent non-Hodgkin lymphoma. Int J Radiat Oncol Biol Phys 2011; 81:e781.</a></li><li><a class="nounderline abstract_t">Russo AL, Chen YH, Martin NE, et al. Low-dose involved-field radiation in the treatment of non-hodgkin lymphoma: predictors of response and treatment failure. Int J Radiat Oncol Biol Phys 2013; 86:121.</a></li><li><a class="nounderline abstract_t">Davis TA, Kaminski MS, Leonard JP, et al. The radioisotope contributes significantly to the activity of radioimmunotherapy. Clin Cancer Res 2004; 10:7792.</a></li><li><a class="nounderline abstract_t">Wiseman GA, Gordon LI, Multani PS, et al. Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial. Blood 2002; 99:4336.</a></li><li><a class="nounderline abstract_t">Gordon LI, Molina A, Witzig T, et al. Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: long-term follow-up of a phase 1/2 study. Blood 2004; 103:4429.</a></li><li><a class="nounderline abstract_t">Witzig TE, Molina A, Gordon LI, et al. Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan. Cancer 2007; 109:1804.</a></li><li><a class="nounderline abstract_t">Emmanouilides C, Witzig TE, Wiseman GA, et al. Safety and efficacy of yttrium-90 ibritumomab tiuxetan in older patients with non-Hodgkin's lymphoma. Cancer Biother Radiopharm 2007; 22:684.</a></li><li><a class="nounderline abstract_t">Witzig TE, Gordon LI, Cabanillas F, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 2002; 20:2453.</a></li><li><a class="nounderline abstract_t">Czuczman MS, Emmanouilides C, Darif M, et al. Treatment-related myelodysplastic syndrome and acute myelogenous leukemia in patients treated with ibritumomab tiuxetan radioimmunotherapy. J Clin Oncol 2007; 25:4285.</a></li><li><a class="nounderline abstract_t">Di M, Ollila TA, Olszewski AJ. Exposure to ibritumomab tiuxetan and incidence of treatment-related myeloid neoplasms among older patients with B-cell lymphoma: a population-based study. Leukemia 2020; 34:2794.</a></li><li><a class="nounderline abstract_t">Guidetti A, Carlo-Stella C, Ruella M, et al. Myeloablative doses of yttrium-90-ibritumomab tiuxetan and the risk of secondary myelodysplasia/acute myelogenous leukemia. Cancer 2011; 117:5074.</a></li><li><a class="nounderline abstract_t">Andrade-Campos MM, Liévano P, Espinosa-Lara N, et al. Long-term complication in follicular lymphoma: assessing the risk of secondary neoplasm in 242 patients treated or not with 90-yttrium-ibritumomab-tiuxetan. Eur J Haematol 2016; 97:576.</a></li><li><a class="nounderline abstract_t">López-Guillermo A, Canales MÁ, Dlouhy I, et al. A randomized phase II study comparing consolidation with a single dose of 90Y ibritumomab tiuxetan vs. maintenance with rituximab for two years in patients with newly diagnosed follicular lymphoma responding to R-CHOP. Long-term follow-up results. Leuk Lymphoma 2022; 63:93.</a></li><li><a class="nounderline abstract_t">Ansell SM, Ristow KM, Habermann TM, et al. Subsequent chemotherapy regimens are well tolerated after radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for non-Hodgkin's lymphoma. J Clin Oncol 2002; 20:3885.</a></li><li><a class="nounderline abstract_t">Justice TE, Martenson JA, Wiseman GA, Witzig TE. Safety and efficacy of external beam radiation therapy for non-Hodgkin lymphoma in patients with prior 90Y-ibritumomab tiuxetan radioimmunotherapy. Cancer 2006; 107:433.</a></li><li><a class="nounderline abstract_t">Peyrade F, Italiano A, Fontana X, et al. Retreatment with 90Y-labelled ibritumomab tiuxetan in a patient with follicular lymphoma who had previously responded to treatment. Lancet Oncol 2007; 8:849.</a></li><li><a class="nounderline abstract_t">Hamadani M, Radford J, Carlo-Stella C, et al. Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma. Blood 2021; 137:2634.</a></li><li><a class="nounderline abstract_t">Hutchings M, Mous R, Clausen MR, et al. Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study. Lancet 2021; 398:1157.</a></li><li><a class="nounderline abstract_t">Ghobadi A, Bartlett NL. CD3xCD20 bispecific T-cell redirectors for relapsed or refractory B-cell lymphoma. Lancet 2021; 398:1109.</a></li><li><a class="nounderline abstract_t">Nastoupil LJ, Chin CK, Westin JR, et al. Safety and activity of pembrolizumab in combination with rituximab in relapsed or refractory follicular lymphoma. Blood Adv 2022; 6:1143.</a></li><li><a class="nounderline abstract_t">Advani R, Flinn I, Popplewell L, et al. CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's Lymphoma. N Engl J Med 2018; 379:1711.</a></li></ol></div><div id="topicVersionRevision">Topic 4755 Version 97.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26124482" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27465588" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Early event status informs subsequent outcome in newly diagnosed follicular lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27298402" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Risk Factors and Outcomes for Patients With Follicular Lymphoma Who Had Histologic Transformation After Response to First-Line Immunochemotherapy in the PRIMA Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1588373" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Survival after relapse of low-grade non-Hodgkin's lymphoma: implications for marrow transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30285560" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Chemotherapy-Free Initial Treatment of Advanced Indolent Lymphoma Has Durable Effect With Low Toxicity: Results From Two Nordic Lymphoma Group Trials With More Than 10 Years of Follow-Up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30481079" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Cause of Death in Follicular Lymphoma in the First Decade of the Rituximab Era: A Pooled Analysis of French and US Cohorts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30793290" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Life expectancy of follicular lymphoma patients in complete response at 30 months is similar to that of the Spanish general population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30573503" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Association of early disease progression and very poor survival in the GALLIUM study in follicular lymphoma: benefit of obinutuzumab in reducing the rate of early progression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32805081" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Prognostic value of POD24 validation in follicular lymphoma patients initially treated with chemotherapy-free regimens in a pooled analysis of three randomized trials of the Swiss Group for Clinical Cancer Research (SAKK).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33729455" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Early progression of disease in follicular lymphoma is a robust correlate but not a surrogate for overall survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36844185" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Survival by First-line Treatment Type and Timing of Progression Among Follicular Lymphoma Patients: A National Population-based Study in Sweden.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34614146" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients on 13 clinical trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31300404" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Early progression after bendamustine-rituximab is associated with high risk of transformation in advanced stage follicular lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25154829" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Rituximab extended schedule or re-treatment trial for low-tumor burden follicular lymphoma: eastern cooperative oncology group protocol e4402.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14976046" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20697092" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20697092" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32810220" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : A phase 3 randomized study (HOMER) of ofatumumab vs rituximab in iNHL relapsed after rituximab-containing therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26282650" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Randomized Phase II Trial Comparing Obinutuzumab (GA101) With Rituximab in Patients With Relapsed CD20+ Indolent B-Cell Non-Hodgkin Lymphoma: Final Analysis of the GAUSS Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10963642" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17470738" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28976863" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Obinutuzumab for the First-Line Treatment of Follicular Lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27345636" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29584548" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Overall Survival Benefit in Patients With Rituximab-Refractory Indolent Non-Hodgkin Lymphoma Who Received Obinutuzumab Plus Bendamustine Induction and Obinutuzumab Maintenance in the GADOLIN Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33973233" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : A phase 3, randomized study of ofatumumab combined with bendamustine in rituximab-refractory iNHL (COMPLEMENT A + B study).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29856692" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Immunochemotherapy With Obinutuzumab or Rituximab for Previously Untreated Follicular Lymphoma in the GALLIUM Study: Influence of Chemotherapy on Efficacy and Safety.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29800121" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Increased Risk of Infectious Complications in Older Patients With Indolent Non-Hodgkin Lymphoma Exposed to Bendamustine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15908650" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18626004" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26655425" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16873669" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20439641" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23843495" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Obinutuzumab (GA101) plus CHOP or FC in relapsed/refractory follicular lymphoma: results of the GAUDI study (BO21000).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29396094" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : R-CHOP, radioimmunotherapy, and maintenance rituximab in untreated follicular lymphoma (SWOG S0801): a single-arm, phase 2, multicentre study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Four Versus Two Years of Rituximab Maintenance (R-maintenance) Following Bendamustine Plus Rituximab (B-R): Initial Results of a Prospective, Randomized Multicenter Phase 3 Study in First-Line Follicular Lymphoma (the StiL NHL7-2008 MAINTAIN study) (abstract 483)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22021664" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Rituximab maintenance for the treatment of patients with follicular lymphoma: an updated systematic review and meta-analysis of randomized trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22021664" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Rituximab maintenance for the treatment of patients with follicular lymphoma: an updated systematic review and meta-analysis of randomized trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24521993" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Pharmacokinetics and safety of subcutaneous rituximab in follicular lymphoma (SABRINA): stage 1 analysis of a randomised phase 3 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28476440" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Efficacy and safety of subcutaneous rituximab versus intravenous rituximab for first-line treatment of follicular lymphoma (SABRINA): a randomised, open-label, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28031173" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Preference for subcutaneous or intravenous administration of rituximab among patients with untreated CD20+ diffuse large B-cell lymphoma or follicular lymphoma: results from a prospective, randomized, open-label, crossover study (PrefMab).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26947201" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Pharmacokinetics, safety, and efficacy of subcutaneous versus intravenous rituximab plus chemotherapy as treatment for chronic lymphocytic leukaemia (SAWYER): a phase 1b, open-label, randomised controlled non-inferiority trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29611177" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Second-line and subsequent therapy and outcomes for follicular lymphoma in the United States: data from the observational National LymphoCare Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29645093" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Autologous transplantation versus allogeneic transplantation in patients with follicular lymphoma experiencing early treatment failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29242111" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Autologous Transplantation in Follicular Lymphoma with Early Therapy Failure: A National LymphoCare Study and Center for International Blood and Marrow Transplant Research Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29966465" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Autologous transplantation improves survival rates for follicular lymphoma patients who relapse within two years of chemoimmunotherapy: a multi-center retrospective analysis of consecutively treated patients in the real world.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30129233" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Autologous stem cell transplantation may be curative for patients with follicular lymphoma with early therapy failure who reach complete response after rescue treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29605716" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Autologous Stem Cell Transplantation for Patients with Early Progression of Follicular Lymphoma: A Follow-Up Study of 2 Randomized Trials from the German Low Grade Lymphoma Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30515755" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Response duration and survival shorten after each relapse in patients with follicular lymphoma treated in the rituximab era.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32678074" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29934343" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Venous thromboembolism in patients with B-cell non-Hodgkin lymphoma treated with lenalidomide: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30897038" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26304886" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Randomized Trial of Lenalidomide Alone Versus Lenalidomide Plus Rituximab in Patients With Recurrent Follicular Lymphoma: CALGB 50401 (Alliance).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30068505" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : An open-label phase 1b study of obinutuzumab plus lenalidomide in relapsed/refractory follicular B-cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30068505" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : An open-label phase 1b study of obinutuzumab plus lenalidomide in relapsed/refractory follicular B-cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29650362" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33035457" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26256760" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32870269" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Efficacy and safety results from CheckMate 140, a phase 2 study of nivolumab for relapsed/refractory follicular lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29851546" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Ibrutinib as Treatment for Patients With Relapsed/Refractory Follicular Lymphoma: Results From the Open-Label, Multicenter, Phase II DAWN Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29074501" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Single-agent ibrutinib in relapsed or refractory follicular lymphoma: a phase 2 consortium trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32785666" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Venetoclax-rituximab with or without bendamustine vs bendamustine-rituximab in relapsed/refractory follicular lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33022066" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Zanubrutinib (BGB-3111) plus obinutuzumab in patients with chronic lymphocytic leukemia and follicular lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35390135" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Zanubrutinib monotherapy in relapsed/refractory indolent non-Hodgkin lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37506346" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : ROSEWOOD: A Phase II Randomized Study of Zanubrutinib Plus Obinutuzumab Versus Obinutuzumab Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37506346" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : ROSEWOOD: A Phase II Randomized Study of Zanubrutinib Plus Obinutuzumab Versus Obinutuzumab Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35429996" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : The saga of PI3K inhibitors in haematological malignancies: survival is the ultimate safety endpoint.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35429996" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : The saga of PI3K inhibitors in haematological malignancies: survival is the ultimate safety endpoint.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35429996" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : The saga of PI3K inhibitors in haematological malignancies: survival is the ultimate safety endpoint.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35429996" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : The saga of PI3K inhibitors in haematological malignancies: survival is the ultimate safety endpoint.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29226764" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31648294" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : High rate of durable complete remission in follicular lymphoma after CD19 CAR-T cell immunotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34921238" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34895487" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34895487" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34914545" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34914545" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34914545" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35803286" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20114084" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of follicular lymphoma: an evidence-based review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18318762" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Outcome of BEAM-autologous and BEAM-alemtuzumab allogeneic transplantation in relapsed advanced stage follicular lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12702528" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Long-term results favor allogeneic over autologous hematopoietic stem cell transplantation in patients with refractory or recurrent indolent non-Hodgkin's lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34380640" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Nine-Year Follow-up of Patients with Relapsed Follicular Lymphoma after Nonmyeloablative Allogeneic Stem Cell Transplant and Autologous Transplant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12893748" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23771004" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : The outcome of reduced intensity allogeneic stem cell transplantation and autologous stem cell transplantation when performed as a first transplant strategy in relapsed follicular lymphoma: an analysis from the Lymphoma Working Party of the EBMT.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23921646" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Stem cell transplantation for follicular lymphoma relapsed/refractory after prior rituximab: a comprehensive analysis from the NCCN lymphoma outcomes project.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26253007" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Reduced-Intensity Allografting as First Transplantation Approach in Relapsed/Refractory Grades One and Two Follicular Lymphoma Provides Improved Outcomes in Long-Term Survivors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20970029" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Localized low-dose radiotherapy for follicular lymphoma: history, clinical results, mechanisms of action, and future outlooks.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21398049" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Low-dose radiotherapy in indolent lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21167657" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Palliation by low-dose local radiation therapy for indolent non-Hodgkin lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23414765" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Low-dose involved-field radiation in the treatment of non-hodgkin lymphoma: predictors of response and treatment failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15585610" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : The radioisotope contributes significantly to the activity of radioimmunotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12036859" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15016644" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: long-term follow-up of a phase 1/2 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17380530" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17979571" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Safety and efficacy of yttrium-90 ibritumomab tiuxetan in older patients with non-Hodgkin's lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12011122" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17709799" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Treatment-related myelodysplastic syndrome and acute myelogenous leukemia in patients treated with ibritumomab tiuxetan radioimmunotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32203140" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Exposure to ibritumomab tiuxetan and incidence of treatment-related myeloid neoplasms among older patients with B-cell lymphoma: a population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21567384" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Myeloablative doses of yttrium-90-ibritumomab tiuxetan and the risk of secondary myelodysplasia/acute myelogenous leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27157440" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Long-term complication in follicular lymphoma: assessing the risk of secondary neoplasm in 242 patients treated or not with 90-yttrium-ibritumomab-tiuxetan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34459702" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : A randomized phase II study comparing consolidation with a single dose of 90Y ibritumomab tiuxetan vs. maintenance with rituximab for two years in patients with newly diagnosed follicular lymphoma responding to R-CHOP. Long-term follow-up results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12228209" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Subsequent chemotherapy regimens are well tolerated after radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for non-Hodgkin's lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16770786" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Safety and efficacy of external beam radiation therapy for non-Hodgkin lymphoma in patients with prior 90Y-ibritumomab tiuxetan radioimmunotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17765194" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Retreatment with 90Y-labelled ibritumomab tiuxetan in a patient with follicular lymphoma who had previously responded to treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33211842" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34508654" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34508653" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : CD3xCD20 bispecific T-cell redirectors for relapsed or refractory B-cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35015819" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Safety and activity of pembrolizumab in combination with rituximab in relapsed or refractory follicular lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30380386" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's Lymphoma.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
